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Foreword
The purpose of this report is to examine data on various
types of formulated diets in order to uncover nutritional
knowledge that may be applied to the design of diets assembled
from fairly restricted groups of sources for long-term space
travel. The study of these special diets is also of great
benefit to the field of nutrition in general.
Compositions of representative commercial diets have been
included to illustrate human dietary requirements. The inclusion
of a dietary formulation is not an endorsement of a specific
product. Many nutritional products that are not mentioned in
this report are available. Exclusion of specific products was
done to avoid repetition of similar formulations and because of
space limitations. More complete descriptions of nutritional
products can be obtained directly from the various manufacturers,
as well as by consulting the latest edition of the Physician's
Desk Reference and other sources.
I wish to thank James Bredt and Pat Groziak for reviewing
this report and April Roy for her excellent typing and editorial
assistance.
This report was prepared for the NASA Life Sciences Division
under contract NASw-3165.
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CHAPTER I
INTRODUCTION
Purpose
One of the most complicated and frequently controversial
areas in human health is nutrition. Although many of the major
nutritional principles have been elaborated in this century, a
large number of questions remain. The effects of specific
nutrients are very difficult to study, due to the large number of
other variables present. These variables include composition of
the diet, genetic background, age, sex, environmental conditions,
psychosocial factors, as well as many interactions between
variables. Humans have been able to survive without
understanding everything about nutrition by eating a varied diet.
When a diet is more restricted, there is a greater risk of
nutrient deficiencies developing over time.
A diet similar to what humans normally consume has been
provided for space missions up to now because these missions
have been of short duration. However, very long space missions
are anticipated sometime in the future. These missions may
require food and oxygen regeneration and waste recycling. The
CELSS (Controlled Ecological Life Support Systems) Program of the
National Aeronautics and Space Administration (NASA) is doing
research on feasible approaches to food selection, food
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production, and nutrient recycling. Due to the great practical
and technical limitations on such missions, the number of species
of plants and/or animals grown or raised will be quite restricted
yet must furnish an adequate diet. It is essential that the best
available understanding of human nutritional requirements be
attained, so that an adequate combination of food sources can be
selected.
The most extensive experience in humans with restricted diets
is in the use of chemically defined diets (CDD's). In these
diets, all of the nutrients are supplied in the form of
relatively simple chemical compounds, so that the composition of
each diet is more exactly determined than in a normal diet. It
was thought that a review of the literature on CDD's would help
the CELSS Program design space diets that could meet human
nutritional requirements with a minimum number of components. An
analysis of CDD's will also identify nutritional areas requiring
further study, which will enable NASA to set the appropriate
priorities.
It should be emphasized that CDD's are not being proposed as
the actual diets for astronauts in this report. Although CDD's
have been investigated by Winitz et al. (1965) for this potential
application, the use of such an extreme diet is no longer being
seriously considered for use in healthy individuals. Liquid
diets tend to be monotonous and various morphological and
physiological changes in the gastrointestinal tract have been
observed in both humans and laboratory animals on CDD's. The
physiological effects of CDD's are discussed in detail later in
this report. A number of unconventional food sources, such as
algae, synthetic proteins and carbohydrates, bacteria, and others
(Popov, 1975), have been investigated as food for space travel.
These unusual sources will probably be combined with more
conventional food sources in any actual system.
Scope
Chemically defined diets are reviewed in terms of the
various types, nutrient compositions, clinical applications,
physiological effects, and experimental studies in humans and
laboratory animals. The major emphasis is on studies in healthy
humans, and there are very few of these compared with those in
seriously ill patients. Regarding the clinical studies, special
consideration has been given to those in which the patients have
been using CDD's for long durations. Human nutritional
requirements that have been more clearly defined as a result of
experience with CDD's are discussed. Current knowledge
about nutrient requirements, toxicities, and interactions is
summarized. Finally, areas are identified where more nutritional
information is needed.
Early Development of CDD's
Chemically defined diets were developed for use in three
situations: i) in the prevention of starvation in severely ill
patients; 2) in diets for astronauts in long-term space travel;
and 3) in conducting precise metabolic and nutritional studies.
The provision of oral nutritional supplements in liquid form
has been attempted throughout history. Certain synthetic
nutrients, such as protein hydrolysates, and some liquid formula
diets were being produced around 1950 (Kark, 1974). The
development of CDD's can be traced through the use of intravenous
(parenteral) feeding techniques, since the chemical composition
of the fluids had to be formulated very precisely to avoid
adverse reactions. The therapeutic use of intravenous fluids
containing specific chemicals, such as salts and sugars, was
first attempted in the 1800's (Shenkin and Wretlind, 1979).
Great advances in the use of parenteral feeding were made
during World War II and in the decade following. Nutritional
requirements for calories and nitrogen were established during
this period (Shils, 1980). The major limitation on intravenous
feeding in seriously ill patients, where the oral route is
impossible, is that very large volumes of fluids are needed to
furnish enough calories. Traditional intravenous techniques use
isotonic fluids in peripheral veins (because these are more
accessible); however, a very ill patient may not be able to
tolerate over three liters of fluid per day (Dudrick and Rhoads,
1972). Since not enough calories may be delivered in three
liters, the result of long-term total parenteral nutrition (TPN)
under these conditions is starvation.
This problem was solved by Dudrick et al. (1968) by infusion
of fluids into a catheter implanted in the superior vena cava
through the external jugular (neck) or subclavian (shoulder)
veins. The superior vena cava is large enough to dilute
hypertonic glucose infusions, which would damage peripheral veins
and alter the osmotic pressure of the blood. The technique was
first tried successfully in puppies for as long as 256 days and
then in humans for up to 200 days. Although the use of TPN has
saved the lives of patients who cannot be fed through the
gastrointestinal tract, it is a drastic measure which is
associated with many complications, particularly infection. Oral
CDD's are used when possible, depending on the patient. The
clinical situations requiring CDD's are discussed in Chapter III.
In order to improve the liquid formula diets for clinical
use, the National Institutes of Health began sponsoring a number
of studies, in which various liquid diet compositions were tested
in rats and mice during the 1950's (Birnbaum et al., 1957-1958;
Greenstein et al., 1957; Winitz et al., 1957; and others). A
nutritionally complete CDD was finally developed in rats
(Greenstein et al., 1960). Further studies supported by NASA
were begun with the goals of chemically improving this CDD for
adaptation to humans and other species and of defining exact
amino acid and trace element requirements (Winitz, 1962).
5
Various CDD's were then evaluated by Winitz et al. (1965) in
healthy adult males with promising results.
The Air Force also became interested in improving formulated
diets in the early 1960's in preparation for both long-term space
travel and more precise nutritional studies. A series of
projects were begun in order to develop CDD's after the Air Force
found that none of the currently available liquid diets were
either adequately defined chemically or palatable enough (Dymsza
et al., 1968). The CDD's in these studies were developed at the
Food Laboratory of the United States Army Natick Laboratories.
In further studies, jointly sponsored by the Air Force and NASA,
CDD's were tested in volunteers (college students) under
simulated space conditions in a Life Support Systems Evaluator
while the subjects wore space suits for 28-day trials (Katchman
et al., 1967; Lotter et al., 1967; Katchman et al., 1970). The
results of these studies in humans and laboratory animals are
summarized in Chapter III.
A final development of CDD's is for the study of basic human
nutrition, which is the major purpose of this report. Most of
the studies on CDD's are clinical in nature, but all have
uncovered information about nutrition that can be applied to
normal individuals. The use of CDD's enables nutritionists to
control dietary constituents more precisely, so that their
effects can be more easily determined. In addition, the
intravenous route of CDD's is useful in nutritional studies,
because it bypasses the problem of differential absorption rates
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of chemical compounds (Shenkin and Wretlind, 1979). Differential
absorption means that different nutrients ingested at the same
time will reach the bloodstream at different times, depending on
the size and structure of each nutrient.

CHAPTER II
HUMAN NUTRIENT REQUIREMENTS AND CHEMICALLY DEFINED DIETS
All CDD's must supply water, energy, essential fatty acids,
amino acids, vitamins, minerals, and trace elements in order to
maintain health. The dietary requirements in healthy adults in
the United States for these nutrient categories are discussed
below. It should be noted that growing children, pregnant or
nursing women, and the very ill generally have increased
requirements. The need for energy and certain nutrients tends to
be reduced in old age. Individual variations in requirements
must also be considered in the design of diets. The various
types of CDD's and the compounds used to satisfy these nutrient
requirements in different formulations are reviewed, and the
compositions of commercially available CDD's are compared.
Basic Requirements
Water
The adult fluid (water) requirement is 1 ml fluid per kcal
(kilocalorie) diet per day (National Research Council, 1980).
Human fluid needs are increased by high ambient temperature,
greater physical exercise, and when certain disease symptoms
(such as diarrhea, vomiting, or fever) are present.
Energy
The number of kilocalories of energy needed for growth,
maintenance of body temperature, and other metabolic activities
varies according to age, gender, amount of daily physical
activity, body size, environmental conditions, and the presence
of various stressful conditions, such as pregnancy, lactation,
injury, or disease. The recommended energy intakes for adults in
the United States are shown in Table i.
Table 1
Recommended Daily Energy Intake:
U.S. Adults
Age Mean Range
(years) (kcal) (kcal)
Men 19-22 2900 2500-3300
(70 kg = 154 ib;
5 ft i0 in tall) 23-50 2700 2300-3100
51-75 2400 2000-2800
76 up 2050 1650-2450
Women 19-22 2100 1700-2500
(55 kg = 121 ib;
5 ft 4 in tall) 23-50 2000 1600-2400
51-75 1800 1400-2200
76 up 1600 1200-2000
Source:
National Research Council, 1980
i0
Protein
Proteins are polymers composed of over 20 different amino
acids, of which 9 are essential (see Table 2). There are a
number of other naturally occurring amino acids that are not in
proteins, but are found in cells and have various metabolic
functions. The amino acids in proteins are all L-alpha-amino
acids.
The amount of protein required per day is 0.8 g per kg body
weight per day (National Research Council, 1980). This is
equivalent to 56 g protein per day for a 70 kg man and 44 g
protein per day for a 55 kg woman. Protein intake should be
about i0 to 15% of the total diet (Harper, 1973). The American
diet includes about ii to 12% protein (National Research Council,
1980). The requirement for protein consists of a need for both
nitrogen and specific essential amino acids (EAA's). The
recommended daily intake of EAA's is listed in Table 3. Proteins
also furnish sulfur and phosphorus in significant amounts.
ii
Table 2
Amino Acids of Human Proteins
Essential Nonessential
Histidine* Alanine**
Isoleucine Arginine**
Leucine Asparagine
Lysine Aspartic acid**
Methionine Cysteine (from cystine)**
Phenylalanine Cystine (can substitute
for 80-90% methionine)
Threonine Glutamic acid**
Tryptophan Glutamine
Valine Glycine (toxic at high
levels)
Hydroxylysine
4-Hydroxyproline
Proline**
Serine**
Tyrosine** (can substitute
for 70-75% phenylalanine)
*Requirements not established for healthy adults; required in
infants and nephritic adults (Calloway, 1975)
**Recommended for a CDD given IV (Shenkin and Wretlind, 1979)
12
Table 3
Recommended Daily Intake of
Essential Amino Acids
g/day (for a 70 kg adult male)
Histidine 2.0
Isoleucine 1.4-1.68
Leucine 2.2-2.24
Lysine 1.6-1.68
Methionine 2.2
Phenylalanine 2.2
Threonine 1.0-1.12
Tryptophan 0.42-0.5
Valine 1.6-1.96
Sources:
Calloway, 1975
National Research Council, 1980
The nitrogen requirement (for synthesis of amino acids) is
fulfilled by nonessential amino acids (NAA's). The terms
"essential" and "nonessential" are somewhat misleading, because
both types of amino acids must be supplied for an adequate diet.
The main distinction is that EAA's cannot be synthesized by the
human, and NAA's can be synthesized. The ability of the human to
synthesize certain NAA's, such as arginine, is somewhat limited
(Shenkin and Wretlind, 1979).
In addition to needing certain amounts of amino acids, humans
also need a certain balance among the amino acids. There are a
number of potential interactions among the amino acids, which
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could create an imbalance if incorrect mixtures are supplied in a
CDD. There are also some amino acids, such as glycine, which are
toxic at high levels (Shenkin and Wretlind, 1979).
Physiologically balanced amino acid mixtures are those that have
EAA patterns similar to proteins in the human body (Vander et
al., 1975), i.e., animal proteins. Whole egg and milk proteins
(casein is a major milk protein) are often used as standards with
which to compare the quality of other proteins. These proteins
are fully utilized by young rats in bioassays for protein
quality.
Another aspect of overall protein quality is digestibility,
which is determined by the amount of nitrogen in the feces
(National Research Council, 1980). Plant proteins are usually
less digestible than animal proteins due to too much fiber, lower
solubility in human digestive fluids, and other factors (Hoff,
Howe, and Mitchell, 1982; Vander et al., 1975). In general,
single plant proteins (except for soybean protein) do not provide
all EAA's. Combinations of plants, such as wheat and peanuts,
cereals and green leafy vegetables and legumes, and corn or rice
plus beans, can provide the right balance of amino acids (Howe
and Hoff, 1982). The plants in each of the combinations should
be ingested at the same time so that the body has all the EAA's
for optimum protein synthesis (Phillips and Odgers, 1982).
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Carbohydrate
Carbohydrates include sugars, starches, and cellulose and are
the main energy sources in the normal diet. Carbohydrates should
comprise about 55 to 70% of the total diet (Harper, 1973). The
National Research Council (1980) states that the current amount
of carbohydrate in the American diet is about 46%, and that
carbohydrates made up a higher fraction of the diet earlier in
this century. Fat intake has increased to nearly the
carbohydrate intake in terms of calories. Although the absolute
minimum intake of carbohydrate should be 50 to i00 g, Calloway
(1975) recommends about 400 to 500 g per day, mainly as the
complex carbohydrate, starch, because solutions with high levels
of simple sugars have high osmolarities (large amounts of
dissolved substances). A sudden increase in osmolarity can be
stressful to the body, whether the substances are taken orally or
intravenously. This is a critical consideration in CDD's and
will be discussed in more detail later.
Fiber
Fiber includes indigestible carbohydrates and other
substances, such as cellulose, lignin, gums, and pectins.
Although there is no proof that a fiber requirement exists,
beneficial effects of fiber have been observed. Fiber is known
to enhance intestinal function, and there is some epidemiological
evidence that people with diets containing very low amounts of
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fiber have higher incidences of cancer of the colon and other
ailments. Although this preventive aspect of fiber has not been
validated, an intake of 2 to 3 g fiber per day is suggested
(Calloway, 1975). Too much fiber, on the other hand, may
interfere with mineral absorption (National Research Council,
1980).
Fat
Fats, or lipids, provide energy and essential fatty acids,
improve food palatability, and act as carriers for the
fat-soluble vitamins (A, D, E, and K). Most dietary fats are
triglycerides (National Research Council, 1980), which consist of
three fatty acids of various lengths attached to glycerol, a
3-carbon carbohydrate. The major essential fatty acid for humans
is linoleic acid, which is abundant in vegetable oils. Although
arachidonic acid is an essential fatty acid, it is produced from
linoleic acid in the body and is not required in the diet (Martin
et al., 1983). Linolenic acid may also be an essential fatty
acid; however, this has not been confirmed in humans. Linolenic
acid occurs in the same vegetable oils as linoleic acid, but in
smaller amounts. Linolenic acid is not synthesized in the human,
and possible linolenic acid deficiency symptoms have been
observed in both humans and animals. If a linolenic acid
requirement exists it is very small, and the dietary ratio of
linoleic to linolenic acids may actually be more important in
human nutrition. These questions are under investigation (Bivins
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et al., 1983). Calloway (1975) states that 3 to 6 g linoleic
acid per day will meet the requirements. The National Research
Council (1980) recommends that at least 1 to 2% of the total
daily caloric intake be essential fatty acids, which are
polyunsaturated.
Other recommendations of the National Research Council (1980)
include decreasing the total portion of fat in the diet from 42%
(in the typical American diet) to 35% and increasing the ratio of
polyunsaturated to saturated fats in the diets. High intake of
saturated fats may be one of the risk factors in coronary artery
disease, although this is still controversial. High intake of
.polyunsaturated oils may also be harmful and no more than 10% of
the diet should be from this source. Too many polyunsaturated
fatty acids may increase the vitamin E requirement and may hasten
aging (Hoff, Howe, and Mitchell, 1982). These investigators
recommend that total dietary fat be approximately 30%.
Vitamins
The vitamins are a group of chemical compounds of various
structures, which are needed for normal metabolism and are either
not synthesized at all in the human or are not synthesized in
large enough amounts without dietary supplementation (Goodhart
and Shils, 1980). The vitamins function as cofactors or
coenzymes for a variety of metabolic reactions. Intestinal
bacteria synthesize small quantities of vitamins. With the
exception of biotin and vitamin K, intestinal vitamin synthesis
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is not adequate to meet adult requirements (Harper, 1973; Vander
et al., 1975). Although the vitamins are not chemically related,
these nutrients are commonly divided into two categories:
water-soluble and fat-soluble.
The water-soluble vitamins include the vitamin B complex
(folacin, niacin--nicotinic acid and nicotinamide, pantothenic
acid, riboflavin or B2, thiamin or B I, pyridoxine or B 6,
cobalamins or BI2 , biotin, and inositol), ascorbic acid or C, and
choline. Although no recommended allowance for inositol has been
established at this time in the United States, about 1 g per day
is recommended in the Soviet Union (Calloway, 1975). Inositol is
essential in mice and chicks and has been found to be necessary
for growth in some experimental human cell cultures (Harper,
1973). Choline is synthesized by the human and an average of
about 400 to 900 mg (milligrams) are ingested daily in the
American diet (National Research Council, 1980). Because no
choline deficiency symptoms have been reported in humans
(although such symptoms have been found in various laboratory
animals), there may not be a human dietary requirement for
choline. The precursors for choline biosynthesis (methionine,
folacin, and vitamin BI2) do have dietary requirements. The
remaining question is whether deficiency symptoms might appear
after long-term absence of dietary choline.
The fat-soluble vitamins are A (retinol), D (ergocalciferol
and cholecalciferol), E (tocopherols), and K (phylloquinone and
18
the menaquinones). Human vitamin requirements from the National
Research Council (1980) and Calloway (1975) are given in Table 4.
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Table 4
Human Vitamin RequirementsI
Vitamin Daily Allowance Recommended
for U.S. Adults
Water-soluble
B complex
Thiamin (B1) 1.0 mg (per 2000 kcal)
Riboflavin (B2) 1.2 mg (per 2000 kcal)
Pyridoxine (B6) 2.2 mg (males);
2.0 mg (females)
BI2 3.0 mcg (micrograms)
Folacin (folic acid) 400 mcg
Niacin (nicotinic acid
and nicotinamide) 13.2 mg/2000 kcal (60 mg tryp-
tophan = 1 mg niacin)
Pantothenic acid 4.0-7.0 mg (estimated safe and
adequate intake)
Biotin 2 100-200 mcg (estimated safe and
adequate intake) 3Inositol Not established in humans
C (ascorbic acid) 60.0 mg
Choline 0.4-0.9 g (average intake--may
not be a vitamin in humans)
Fat soluble
A 1.0 mg (5000 IU) males;
0.8 mg (4000 IU) females
D 0 (for adults exposed to
sunlight)
200.0 IU (with no exposure
or inadequate exposure to
sunlight)
E I0.0 IU (males) ;
8.0 IU (females) ;
30.0 IU for astronauts 3
K2 70.0-140.0 mcg (estimated safe
and adequate intake)
References:
i. From National Research Council (1980) unless indicated
2. No requirement established due to synthesis by intestinal
microorganisms
3. Calloway (1975)
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Minerals
Essential elements assist in the activation of various
enzymes, in the electrophysiology of nerves and muscles, and in
many other complex bodily functions. The minerals that are
required in relatively large amounts are commonly called
macronutrients and include calcium, chlorine, magnesium,
phosphorus, potassium, and sodium. Sulfur is also required;
however, this requirement is met by intake of the amino acids,
cysteine and methionine. Calcium and phosphorus combine to form
the structural part of bones and teeth and function in other
metabolic processes. Magnesium is combined with calcium and
phosphorus in bone, is involved in various enzyme systems, and
maintains the electrical potential of nerves and muscles. These
three minerals must be present in certain ratios for optimal
health. The ratio of calcium to phosphorus should be about I:i
and that of calcium to magnesium should be about 2:1 (Calloway,
1975). The condition of weightlessness in space travel has
produced calcium losses and imbalances leading to bone loss in
astronauts (Nicogossian and Parker, 1982; Rambaut, 1980).
The function of the electrolytes--sodium, potassium, and
chlorine--is to regulate water metabolism. The requirements for
sodium in particular are the subject of an ongoing controversy.
The relationship of high sodium intake to the development of
hypertension remains unresolved. Certain individuals are at
least susceptible to developing hypertension and may be more
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sensitive to sodium intake. Vander et al. (1975) estimate that
the American intake of table salt (sodium chloride, which is the
source of most dietary sodium) is an average of i0 to 15 g per
day. The intake of sodium alone is estimated to be from 2.3 to
6.9 g per day in a typical American adult (National Research
Council, 1980). The National Research Council recommends that
this intake be reduced to between i.i and 3.3 g per day with a
maximum of 5 to 6 g per day.
To complicate this issue, other minerals may be involved in
hypertension. Kurtz and Morris (1983) have suggested that the
intake of chloride rather than sodium alone, may be important in
the development of hypertension. A pilot survey comparing the
dietary habits of normotensive versus hypertensive individuals
found that while the sodium and potassium levels between the two
groups did not differ significantly, the calcium intake was
significantly lower in hypertensives (McCarron et al., 1982).
The daily mineral allowances for adults (National Research
Council, 1980) are given in Table 5.
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Table 5
Daily Mineral Allowances for U.S. Adults*
Calcium 0.8 g
Magnesium 0.35 g (males); 0.3 g (females)
Phosphorus 0.8 g
Chlorine (as chloride)** 1.7-5.1 g
Potassium** 1.875-5.625 g
Sodium** 1.1-3.3 g (5-6 g maximum)
*National Research Council, 1980
**Estimated safe and adequate intake
Trace Elements
The functions of and dietary requirements for the trace
elements, or micronutrients, are still under study. For an
element to be deemed essential, it must be naturally occurring
and must be found in the newborn (or in breast milk), in the egg,
and in various organs (Schwarz, 1977). Essentiality is further
defined by discovery of a specific physiological function of the
element. Essential trace elements are required in very small
amounts and are toxic at higher levels. A number of trace
elements have been added to the list of essential nutrients for
humans in the past 20 to 30 years. Future research will
undoubtedly uncover more essential trace elements, will more
precisely define the requirements for them, and will clarify
various interactions among them.
The trace elements whose requirements have been the most
well-defined are iron, iodine, and zinc (Calloway, 1975). The
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requirements for the trace elements are the result of studies in
laboratory animals, limited experimental studies in humans,
calculations of the normal daily dietary intake in the United
States, calculations of the amounts excreted in healthy humans,
and the presence of deficiency symptoms in certain individuals
(which are ameliorated by administration of the element). Copper
deficiency is relatively rare in healthy humans and is more
commonly observed in individuals suffering from malnutrition, in
premature infants, and after long-term total parenteral nutrition
(Bozzetti et al., 1983; National Research Council, 1980).
Deficiency symptoms in healthy humans are rare for chromium,
manganese, molybdenum, and selenium, however, animal studies have
provided evidence that these elements are required by humans
(National Research Council, 1980).
The chromium requirement is not easily defined, because the
element varies in form and availability, and the amount actually
absorbed from the diet is very small. As with all nutrients,
essentiality is best shown by observing deficiency symptoms in
humans. The most clearly documented cases of chromium deficiency
have been reported in TPN (Total Parenteral Nutrition) patients.
One case occurred in a woman after 3 1/2 years with no chromium
in the TPN solution. The woman lost weight, developed
neuropathy, and had abnormal glucose, fat, and nitrogen
metabolism. Large initial doses of chromium were given for 2
weeks, after which a daily dose of 20 mcg (micrograms) had been
given for 18 months with no further symptoms at the time of
24
publication (Jeejeebhoy et al., 1977). Since normal plasma
insulin levels occurred along with the deficiency symptoms, this
case provided evidence of chromium's role as a possible cofactor
for insulin.
Manganese deficiency has not been reported in either normal
humans or in patients on CDD's (manganese is usually included in
oral CDD's and TPN solutions). The functions of manganese in
human enzymes have been well-documented, and deficiencies have
been induced in animals. Manganese is involved in the enzymes
that lead to the formation of oligosaccharides, proteoglycans
(mucopolysaccharides), and glycoproteins. These classes of
compounds contribute to the structure of connective tissue and
cell membranes and are involved in the immune system and many
other complex areas. Manganese is also needed for the enzyme
superoxide dismutase, which appears to protect cells against the
effects of oxygen (Martin et al., 1983). Deficiency of
manganese in animals results in abnormal bones and cartilage,
retarded growth, birth defects, and decreased reproductive
capacity (National Research Council, 1980).
Molybdenum is needed for proper functioning of three
enzymes: aldehyde oxidase, xanthine oxidase, and sulfite oxidase.
The functions of these enzymes are, respectively, the metabolism
of aldehyde and various nitrogenous compounds, conversion of
xanthine to uric acid, and the metabolism of the sulfur amino
acids, methionine and cystine. The only case of molybdenum
deficiency in a human was reported by Abumrad et al. (1981). A
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male patient aged 24 had been on TPN for about one year, after
which he began experiencing severe symptoms from administration
of various amino acid solutions. The physical symptoms included
nausea, vomiting, headaches, increased pulse and breathing rates,
and coma. The biochemical changes included high levels of
methionine in the blood, decreased excretion of inorganic sulfate
and uric acid, and increased excretion of organic sulfate and
xanthine. These changes were not induced by other nutrient
solutions, and the symptoms were reversible when the amino acid
infusions were withdrawn. A daily dose of 300 mcg ammonium
molybdate was able to correct the severe reactions to amino acid
infusions.
Selenium deficiency has been reported recently in a male
patient on TPN without selenium for over a year. There
were no obvious symptoms; however, low selenium levels and low
activity of the enzyme glutathione peroxidase (for which selenium
is a cofactor) were detected in the blood. Selenium was
administered at a dose of 400 mcg per day for one week and then
i00 mcg per day. After 4 months of selenium therapy, the
blood tests returned to normal (Baker et al., 1983).
A summary of the trace element requirements is given in
Table 6. Elements have been included that are suspected to be
essential for humans, but no requirements have been set due to
insufficient data. Requirements for these elements are expected
to be set in the future.
26
Table 6
Essential Trace Element Requirements
Element Recommended Daily Intake 1
Essentiality demonstratedl:
Cobalt In vitamin BI2
Copper 2.0-3.0 mg
Chromium 50.0-200.0 mcg
Fluorine (as fluoride) 1.5-4.0 mg (adult)
1.5-2.5 mg (younger
groups)
Iodine 150.0 mcg
Iron i0.0 mg (males)
18.0 mg (females)
Manganese 2.5-5.0 mg
Molybdenum 0.15-0.5 mg
Selenium 50.0-200 mcg
Sulfur in methionine and cysteine
Zinc 15 0 mg
Essentiality suspected I-5..
Aluminum Not established
Arsenic ,,
Cadmium "
5
Nickel 75.0 mcg (hypothetical)
Silicon Not established
Tin ,,
Vanadium "
References:
I. National Research Council, 1980
2. Rambaut, 1980
3. Schwarz, 1977
4. Mertz, 1981
5. Solomons et al., 1982
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Types of CDD's and Sources of Nutrients
The phrase, "chemically defined diet," as used in the
biomedical field, is somewhat ambiguous. This is because there
are different degrees to which a CDD may be defined and because
none of these diets are completely specified down to the last
molecule. Both Heymsfield et al. (1979) and Bloch and Shils
(1980) have suggested that DFD (defined formula diet) would be
more accurate. For the purposes of this report, the term CDD
includes diets administered in liquid form that are purified or
semipurified, are low residue, and may include intact protein
and small amounts of lactose. This type of diet is in contrast
to either a diet of solid food or a liquid diet made entirely
from homogenized solid food.
Chemically defined diets differ in the way they are
administered, in the specific compounds used in each nutrient
category (i.e., protein, fat, carbohydrate, etc.), and in the
amounts of each nutrient used. There are different types of
CDD's for clinical use in order to meet the needs of patients
with specific diseases. For example, those patients with the
inability to absorb fat properly would need diets lower in fat
than normal, and diabetics would need diets lower in simple
sugars. Similarly, patients with a functioning gastrointestinal
(GI) system would be able to receive liquid CDD's orally (by
mouth or by stomach tube). Patients with large portions of their
GI systems removed may have to be fed intravenously. Intravenous
(IV) feeding of a complete diet is commonly called total
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parenteral nutrition (TPN) or IV hyperalimentation. The latter
term is misleading, because not all TPN patients receive excess
calories (Shils, 1980). Nevertheless, the term is still used in
the literature. TPN serves as an artificial intestinal tract
(Grundfest et al., 1979). The normal intestine absorbs nutrients
from digested food and transfers them into the bloodstream. TPN
performs this function by putting nutrients directly into
circulation via a central vein (usually the superior vena cava in
the chest).
Fats
The compositions of oral and intravenous CDD's are similar;
the major differences are in the fats and micronutrients (Voitk,
1975). Since fats are not water-soluble, they are supplied in
the form of an emulsion. For IV administration, the fat
emulsions must be very stable, so that large fat particles (which
could lead to blocked blood vessels in major organs) do not form.
An early fat emulsion, Lipomul, was associated with serious side
effects and had to be taken off the market in 1964 by the United
States Food and Drug Administration (Dudrick and Rhoads, 1972).
Safer fat emulsions were developed and approved for use in the
United States beginning in 1977 (Shils, 1980). The fat emulsions
in current use consist of i00 to 200 g vegetable oil (soybean or
safflower oil), 12 to 20 g of an emulsifier (egg-yolk
phospholipids, soybean lecithin, or soybean phospholipids), 25 to
50 g of a compound (sorbitol, xylitol, or glycerol) to make the
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emulsion isotonic (same osmotic pressure) with blood, and enough
distilled water to make one liter, allowing for the volume
displaced by the other substances (Shenkin and Wretlind, 1979).
The fats used in oral CDD's are similar, although the
suspensions do not have to be as stable, since there would be no
possibility of blocked blood vessels. Vegetable oils, such as
safflower, soy, or corn, are used alone or in combination with
mono- or diglycerides to stabilize the suspension and medium
chain triglycerides (MCT's). The MCT's are formed from the
fractional distillation of coconut oil and contain fatty acids
with 6 to i0 carbon atoms. They are very easily digested and
increase the absorption of the long chain triglycerides
(Chernoff, 1981; Phillips and Odgers; 1982), which contain fatty
acids of 16 to 18 carbons and are found in vegetable oils
(Phillips and Odgers, 1982; Smith and Heymsfield, 1983).
Vitamins and Trace Elements
Vitamin and trace element doses for TPN solutions have been
based on oral doses. The requirements for these nutrients in
parenteral nutrition are less understood, and there are potential
problems with both inadequate and excessive doses (Voitk, 1975).
With oral intake of food, there is a regulatory system in the
intestine that prevents excess absorption of certain nutrients,
depending on the individual's needs. In IV intake of nutrients,
this regulatory system is bypassed, and all nutrients
administered get into the bloodstream (Shenkin and Wretlind,
3O
1979).
The American Medical Association (AMA) issued some guidelines
for parenteral vitamin doses in 1975 and then updated these
statements 4 years later (American Medical Association, 1979b).
The updated recommendations are similar to the original ones.
The major point is that in 1979 none of the parenteral or
intramuscular multivitamin products satisfied all of the
guidelines. The available products contained excesses or
deficiencies of certain essential vitamins, lacked other
essential vitamins, and were not specific to the requirements of
children versus adults. The manufacturers have subsequently
reformulated many of the products to reflect AMA guidelines.
General recommendations for adults included increased levels of
the water-soluble vitamins (to compensate for stress in patients)
and decreased amounts of vitamin A (the oral requirement is
larger because it is based on absorption and conversion of
carotenes to vitamin A) compared with levels recommended by the
National Research Council in 1974. The AMA stated that its
guidelines are preliminary until more accurate scientific data on
vitamin requirements for long-term parenteral nutrition are
available. Some of the current parenteral vitamin formulations
will be discussed later in this chapter.
Vitamins and trace elements are generally included with
all other substances in one solution for oral CDD's. Modular
vitamins, minerals, and trace elements are available for both
parenteral and oral use. In TPN, these nutrients tend to be
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added separately and may not be included on a daily basis. The
dose schedule depends on the physician's judgment and the needs
of the patient. For example, Greig et al. (1982) give most of
the vitamins 6 days per week; on day 7, vitamins A and D are
given. Vitamin E, which is fat-soluble, is included in the fat
component of the TPN solution. Biotin was not generally supplied
by this group, and this appears to have been standard practice.
Since biotin deficiency in TPN patients has been reported
recently (Innis and Allardyce, 1983; Levenson, 1983) biotin
supplementation is becoming standard practice. Howard et al.
(1983) have found in their clinical experience that TPN patients
can be given larger supplements of vitamin C, thiamin, niacin,
pyridoxine, and folic acid twice weekly. Adding substances less
frequently in home TPN prevents possible contamination of the
solutions, which are made up by the patients. Since TPN is being
used in more and more cases, a better understanding of human
micronutrient needs can be expected in the near future.
An additional problem with micronutrients in CDD's is that
trace elements are widely distributed in nature and are often
present as contaminants in water and other substances. An
analysis of various standard nutrient solutions (amino acids,
lipids, carbohydrates, and salts) for TPN showed that zinc,
copper, chromium, iron, and manganese were present (other trace
elements were not being tested). Zinc and copper were present in
almost every solution tested; the other three were found less
often (Shils, 1980). The exact amount of each element will thus
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be different in every CDD, even if supplemental elements are
added in carefully measured amounts. Hauer and Kaminski (1978)
reported that the chromium present as a contaminant in standard
TPN nutrient solutions may be adequate for human nutritional
needs. Zinc levels were low in the majority of TPN solutions
tested, and all of the commercial solutions were deficient in
iron and copper.
Guidelines for the trace element amounts in TPN solutions
were issued by a panel of experts of the AMA (American Medical
Association, 1979a). At that time, commercial solutions
containing iron, iodine, and cobalt (as vitamin BI2) were already
available. The AMA recommended that zinc, copper, chromium, and
manganese be produced commercially as separate solutions, to
avoid possible overdoses and to meet individual requirements.
The AMA gave the following recommendations for daily IV intake of
each of these elements in clinically stable adults: zinc, 2.5 to
4.0 mg; copper, 0.5 to 1.5 mg; chromium, 0.01 to 0.015 mg;
manganese, 0.15 to 0.8 mg. The AMA also stated that
manufacturers should be required to analyze their TPN solutions
to determine the exact amounts of each trace element present as a
contaminant.
The AMA did not recommend including in TPN therapy other
trace elements that are suspected of being essential, until
further information on human requirements is available. These
trace elements are selenium, vanadium, molybdenum, nickel, tin,
silicon, and arsenic. Since deficiencies of both selenium and
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molybdenum have been reported (Abumrad et al., 1981; Baker et
al., 1983) and since recommended dietary allowances of these two
elements are now available (National Research Council, 1980),
these elements are becoming part of long-term TPN and oral CDD
therapy. Current practice in TPN tends to include zinc,
chromium, copper, and manganese (Seltzer, 1983); the others have
been included only when indicated. Zinc, copper, and manganese
are included in most oral CDD's.
Minerals and Proteins
The levels of macronutrients, including minerals and
electrolytes, are of great importance in CDD's. This is
especially the case in critically ill patients on TPN, because
many of these individuals have a metabolic imbalance of water and
electrolytes. Human requirements for calcium, phosphorus, and
magnesium may be lower IV than orally (Heymsfield et al., 1979).
The commercial amino acid solutions made from protein
hydrolysates contain various amounts of the macronutrients (and
micronutrients) as contaminants and as normal parts of the amino
acid solutions. The commercial crystalline amino acids tend to
have lower amounts of electrolytes (Shils, 1980). Separate
electrolyte solutions for supplementation are also available.
Amino acids in all types of CDD's are given as either
protein hydrolysates or crystalline (synthetic) amino acid
solutions. Positive nitrogen balance has been attained in
patients receiving either amino acid source (Shils, 1980). The
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use of synthetic amino acids allows more flexibility in the
composition of the CDD, because a single amino acid can be added
in a smaller or larger amount to meet individual requirements.
Some protein hydrolysates have been found to have amino acid
imbalances, and these solutions contain some D-forms of amino
acids, most of which humans cannot use. The crystalline amino
acids are now used more commonly in TPN (Phillips and Odgers,
1982). Protein hydrolysates, crystalline amino acids, and intact
proteins are all used in complete CDD's for oral administration.
The advantages of intact proteins are better taste and fewer GI
upsets. Synthetic amino acid solutions have a bitter taste and
higher osmolality, which is increased by the addition of
flavoring ingredients (Smith and Heymsfield, 1983).
Carbohydrates
The carbohydrate components of CDD's must be carefully
selected to avoid exceeding safe osmolarities. Osmolarity is a
measure of how many substances are dissolved in a solution. It
is defined as the number of separate solute particles in the
total volume of solution. The units are in osmoles (Osm) per
liter of solution. The solute concentration is also expressed as
the osmolality--the number of solute particles per unit solvent
measured in osmoles per kg solvent. These units are more
commonly expressed in terms of milliosmoles (mOsm). Substances
that ionize create more solute particles. For example, sodium
chloride breaks into sodium and chloride ions in solution. A one
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molar solution of sodium chloride (one molecular weight in grams
of sodium chloride per liter) is 20sm per liter. Glucose,
proteins, and amino acids do not ionize in solution--a one molar
solution of each of these types of compounds would have an
osmolarity of 10sm per liter. Osmolarity only includes the
number of particles in solution, not the sizes or chemical
properties of the particles (Vander et al., 1975).
Plasma has an osmolarity of about 280 mOsm per liter, and
human red blood cells have an osmolarity of about 300 mOsm per
liter (Vander et al., 1975). If a large amount of a solution
with a higher osmolarity than blood (i.e., a hypertonic solution)
rapidly gets into the bloodstream, a number of adverse
physiological effects can result. Intravenous administration of
very hypertonic solutions can cause inflammation of the veins,
blood clots (Dudrick and Rhoads, 1972), dehydration, and coma
from acute hyperglycemia (Shils, 1980). Oral intake of solutions
with high osmolarities (or osmolalities) may result in GI upsets,
such as nausea and abdominal cramps, diarrhea, vomiting,
sweating, and fainting. These symptoms are the result of the
"dumping syndrome," in which large amounts of fluid enter the
upper intestine in order to dilute the hyperosmolar environment
(Case et al., 1981a; Vander et al., 1975). Normal, solid-food
diets include hypertonic meals with no adverse effects, and a
moderate degree of osmolarity (700 mOsm per liter) has been
reported to be beneficial in promoting nutrient absorption (Case
et al., 1981b). These investigators hypothesized that problems
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with moderate osmolarity may be due to the presence of substances
that are difficult to absorb. The recommended osmolality range
for a complete enteral diet is from 300 to 700 mOsm per kg (Smith
and Heymsfield, 1983).
Despite problems with high osmolarity, glucose (dextrose) is
currently the best carbohydrate source for intravenous feeding.
This is because glucose is needed by the brain, it can be
metabolized by all cells, and it may be monitored easily by blood
tests. Under severe stress, less insulin may be produced by the
body, leading to glucose intolerance. This problem can be
corrected by the addition of insulin to the TPN solution (Shenkin
and Wretlind, 1979). Various substitutes for intravenous
glucose, such as maltose, sorbitol, xylitol, and fructose, have
been tested in humans and laboratory animals (Young and Weser,
1975). Further research is needed before an alternative
carbohydrate becomes used clinically. Since fats can be an
excellent source of energy, combinations of fat and glucose have
been used successfully. Although the ideal ratio is unknown, the
use of 30 to 50% fat and the rest glucose as the energy sources
has produced very promising results, such as increased protein
synthesis (Greig et al., 1982). MacFie et al. (1983) compared
glucose (25%) alone with glucose plus Intralipid (20%) as the
energy sources in two groups of TPN patients. When glucose alone
was the energy source, more energy was used for fat synthesis and
less was available for protein synthesis.
A greater variety of carbohydrates can be used in oral
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CDD's, without the adverse effects observed in IV administration.
Some of the carbohydrates in common use are combinations of
glucose or sucrose with oligosaccharides (composed of 2 to i0
simple sugars), glucose alone, and maltodextrin. Maltodextrin is
formed from the hydrolysis of corn starch and contains mainly
glucose polymers and a few simple sugars such as maltose (Mead
Johnson & Company, 1984). No starch modules are available as
energy sources (Smith and Heymsfield, 1983). In addition to
carbohydrates added as energy sources, others serve as flavorings
and other additives. The flavor additives increase the
osmolarity of the CDD's (Young et al., 1975), but are of obvious
psychological benefit to the patient.
Commercially Available CDD's
Due to the increasing use of CDD's, a large variety of
nutrient formulations are being manufactured. These include
products providing a complete diet, various combinations of two
or more nutrients, and single-nutrient modules that can either be
combined to form a complete diet or used as supplements. Low
residue CDD's contain proteins of a nonmilk (lactose-free)
origin, including egg albumin, soy protein, or casein.
"Low-residue" refers to the fact that less bulky feces are
produced, placing less strain on the intestines. Polymeric CDD's
contain intact protein, have higher molecular weight components,
low osmolalities, and are less costly. Patients receiving
polymeric CDD's must be able to digest protein and fat normally_
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Monomeric CDD's have high osmolalities, are low or lacking in
starches and triglycerides, are more costly, and can be used with
patients who cannot digest protein and fat normally. Monomeric
CDD's are typically prescribed for patients with inflammatory
bowel disease and with chronic diarrhea (Heymsfield et al.,
1979).
The cost of an oral CDD can be less than $50 per day for
2000 kcal (Chernoff, 1981). Wholesale prices in 1978 (per i000
kcal) for several of the complete CDD's were as follows:
Flexical, $3.99; Vital, $4.43; Vivonex, $4.50 (Koretz and Meyer,
1980). Flavoring packages are available at additional cost.
Home TPN can be considerably more expensive, and there is a
greater potential for medical complications (see Chapter III).
The cost for the TPN solutions plus the infusion pump and other
equipment was estimated by Shils (1980) to be from $13,000 to
$24,000 per year. Malcolm et al. (1980) reported that yearly
costs for home TPN in various patients ranged from $i0,000 to
over $50,000.
Although space does not allow for a complete discussion of
the composition of each CDD available, representative CDD's have
been summarized. The data for the CDD's discussed are shown in
Tables 7 through 22 at the end of this chapter. Table 22 lists
all of the CDD's mentioned, giving the nutrient type and
manufacturer's name and address. The compositions are compared,
and nutrient deficiencies and excesses are discussed where
relevant.
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It should be noted that there is a very high turnover among
nutritional products. During the preparation of this report,
some of the products listed below were discontinued and/or
reformulated. A major reason for the turnover is that
pharmaceutical companies change their products to reflect new
medical findings regarding nutritional requirements, side
effects, patient acceptance, and other factors. Those products
that were no longer available at time of publication are so noted
in Table 22.
Comparison of Nutrients in Commercial CDD's
The compositions of four complete enteral CDD's--Flexical,
Vital High Nitrogen (to be referred to as Vital), Standard
Vivonex (to be referred to as Vivonex), and Precision Isotonic--
are shown in detail. Precision Isotonic is a polymeric diet; the
others are monomeric. Compositions of a number of modular
nutrient formulations for both IV and enteral use are also given.
The CDD's selected for inclusion in the tables are basic diets
and solutions not designed for patients with highly specialized
or unusual dietary needs (beyond the inability to tolerate solid
food). For example, a number of commercial diets are available
for various metabolic diseases, such as Maple Syrup Urine
Disease, phenylketonuria, and tyrosinemia (Bloch and Shils,
1980). The CDD's are commonly diluted to 1 kcal per ml or about
i000 kcal per liter (Heymsfield et al., 1979), although the
dilution varies, particularly in the modular preparations. Many
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of the nutrient levels in the tables below are given per I000
kcal. It should be noted that about 2000 kcal of a CDD would be
administered.
Carbohydrates
Tables 7 and 8 list the carbohydrates in some commercial
diets and modular preparations, respectively. The percentage of
calories contributed by the carbohydrate sources to the whole
diets ranges from 60 to 90.5, compared with about 46% in a
typical diet in the United States (National Research Council,
1980). The National Research Council recommends that
carbohydrates be 55 to 70% of the diet. The carbohydrates in
the complete CDD's include sucrose, glucose polymers, and
maltodextrin. The modular carbohydrate solutions available
include maltodextrin (in Moducal), glucose polymers (in
Polycose), or glucose alone (for parenteral use).
Fats
The fat components in some common CDD's are given in Tables
9 to ii. The percentage of fat in the complete diets ranges from
1.3 to 30%, and the percentage of total kilocalories which are
essential fatty acids varies from 1 to 10%. These amounts are
acceptable nutritionally, although the 1% essential fatty acids
in Vivonex is at the lower limit of the range (i to 2%)
recommended by the National Research Council (1980). Most of the
complete diets and modular fat solutions include emulsifiers.
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Greater stability is attained when maltodextrins or other larger
carbohydrates are also used in the diet, when the fat components
comprise less than 30% of the total kilocalories, when the fat is
added at room temperature, or when the complete diet is mixed
every day (Smith and Heymsfield, 1983). The breakdown of
individual fatty acids in the oils used as fat sources is given
in Table ii. Linoleic acid is the main constituent of the
polyunsaturated oils, safflower and corn. Both oils also contain
significant amounts of oleic and palmitic acids, and soybean oil
also contains almost 8% linolenic acid (Phillips and Odgers,
1982). Soybean oil is used in Flexical, Precision Isotonic, and
the parenteral solution Intralipid. Safflower oil is found in
Vital and Vivonex. Medium chain triglycerides are utilized, in
addition to the polyunsaturated oils stated above, in Flexical
and Vital.
Proteins
The proteins in CDD's include synthetic or crystalline amino
acids, hydrolyzed natural proteins, and intact proteins (Tables
12 and 13). As stated earlier in this chapter, those diets
containing intact protein (e.g., Precision Isotonic) are
polymeric and are not considered to be chemically defined in the
strict sense, but have been included for comparison purposes.
This type of diet contains more well-defined carbohydrate and fat
components. The proteins in the complete CDD's (see Table 12)
contribute from 8.2 to 16.7% to the total energy in the diet.
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This range is comparable to that--10 to 15%--recommended by
Harper (1973), as well as to that of the typical American protein
intake--about ii or 12% of the total diet (National Research
Council, 1980).
Synthetic (crystalline) amino acids are the protein sources
in Vivonex (a complete oral CDD) and in the parenteral protein
solutions, Travasol and Freamine III. The synthetic amino acid
solutions are available in different concentrations from 5.5 to
10%. Hydrolyzed casein is found in Flexical, and a combination
of hydrolyzed meat, soy, and whey proteins is in Vital. The
modular oral protein products, Pro Mix and Casec, contain the
intact proteins, whey and calcium caseinate, respectively.
Precision Isotonic contains intact protein in the form of egg
albumin (from pasteurized egg white solids). Single synthetic
amino acids are also available (Smith and Heymsfield, 1983).
The nutritional value of the intact milk proteins, whey and
casein, is very high. Intact protein solutions also have lower
osmolalities and a superior taste compared with other protein
sources, as stated previously. The natural mineral and
electrolyte levels of intact proteins and hydrolyzed proteins are
higher than those of synthetic amino acid solutions. The modular
intact protein products are subjected to a demineralization
treatment, which lowers but does not completely remove all the
minerals (Smith and Heymsfield, 1983). Residual mineral levels
for Casec and Pro Mix have been included in Table 13. The
electrolyte levels added to the parenteral amino acids are also
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given. Mineral and trace element levels of specific CDD's will
be discussed in more detail later.
The amino acid levels of the complete CDD's and the modular
protein sources are listed in Tables 14 and 15. The essential
amino acid levels can be compared with the recommended daily
intakes in Table 3. The minimum daily requirement for each
essential amino acid is half the recommended daily intake
(Harper, 1973). All of the essential amino acids are provided in
the CDD's listed. There is greater variability in the
nonessential amino acids provided, and there are some unanswered
questions about the desirable amount of each one. Research from
the parenteral administration of amino acids (Shenkin and
Wretlind, 1979) has suggested which nonessential amino acids
should be included (see Table 2) and which ones are toxic at very
high levels (aspartic acid, glutamic acid, and glycine). Of the
recommended nonessential amino acids, cystine and glutamic acid
are not included in Vivonex and Travasol, glutamic acid and
tyrosine are absent in Freamine III, and serine is absent in
Travasol. The above suggestions regarding nonessential amino
acids may not apply to orally administered proteins, either
intact or hydrolyzed.
Vitamins
The levels of vitamins (per i000 kcal) in the complete oral
CDD's are shown in Table 16. These levels may be compared with
the recommended daily intakes listed in Table 4. About twice the
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levels listed in Table 16 (2000 kcal) would normally be ingested.
All four CDD's contain amounts of vitamins that either meet or
exceed the recommended intakes in Table 4. Choline may not be a
vitamin for humans because the body can synthesize it. The
average daily dietary intake of choline is about 400 to 900 mg.
Of the three complete CDD's, only Flexical provides this amount
in 2000 kcal. The effects of a lower than average intake of
choline over long periods are unknown. Until there is more
information, lower dietary intakes of choline may be considered
adequate, as long as the choline precursors (methionine, folacin,
and vitamin BI2 ) are provided in the diet.
Three of the modular vitamin preparations are listed in Table
17. As explained previously, the requirements for parenteral
vitamins differ from those of enteral vitamins. The American
Medical Assocation (1979b) has set guidelines for parenteral
vitamin doses, and both multivitamin products listed in the table
(Berocca Parenteral Nutrition and M.V.C. 9+3) conform to these
guidelines. Another parenteral product, M.V.I.-12, has the same
vitamin levels (Physician's Desk Reference, 1984). The vitamin
levels are identical in Berocca and M.V.C. 9+3; only the
additives and manufacturers differ. Vitamin K is not included in
these products because it can interact with anticoagulants used
in certain patients. It is recommended that vitamin K be given
separately 2 to 4 mg per week in patients not receiving
anticoagulants. The parenteral products do not include choline.
NUTRISOURCE is a new group of products, which includes intact
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protein, amino acid, carbohydrate, fat, vitamin, and
mineral/trace element modules for enteral feeding. The vitamin
levels in the NUTRISOURCE module conform to the National Research
Council (1980) guidelines (see Table 4) except in choline. The
average daily intake of choline in the American diet is estimated
at 400 to 900 mg. Since choline is synthesized by the human, it
is not certain that there is a dietary need for choline. For a
patient on a formulated diet for long periods, the i00 mg daily
level of choline in NUTRISOURCE may be adequate, but this is
uncertain.
Minerals, Electrolytes, and Trace Elements
The minerals and electrolytes (per i000 kcal) in complete
CDD's are given in Table 18. See Table 5 for the recommended
daily allowances of these substances. The levels recommended for
sodium, potassium, and chlorine have not yet been determined.
The levels in Table 5 thus are estimated safe and adequate
intakes rather than specific requirements, vivonex contains
1.444 g chloride in 2000 kcal, compared with the 1.7 to 5.1 g
listed in Table 5. Precision Isotonic is the only diet in Table
18 that contains sodium at the safe and adequate intake level
indicated in Table 5. The other three CDD's contain under a gram
of sodium in 2000 kcal. This may not be harmful because the
minimum requirement for sodium in adults may be as low as 58 mg
per day to maintain health (National Research Council, 1980).
The trace element levels (per i000 kcal) of the complete
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CDD's are given in Table 19. The requirements for these elements
are in Table 6. Copper, iodine, iron, manganese, and zinc are
provided within the required ranges in the four CDD's. Vivonex
and Precision Isotonic (Sandoz Nutrition, 1984; Physician's Desk
Reference, 1984) include chromium, molybdenum, and selenium.
These elements would need to be supplemented in long-term use of
Flexical or Vital. Cobalt and sulfur are not added to any of the
diets, because these elements are present in other nutrients (in
vitamin BI2 and in cysteine and methionine, respectively). None
of the CDD's contain added fluoride. Fluorine is present as
fluoride in many drinking water supplies (also soils, plants, and
animals) and is associated with reduced dental caries at a total
intake level of 1.5 mg per day or more. A water supply
containing 1 mg per liter fluoride would produce the desired
total daily intake from food plus water. Fluoride maintenance
levels from 0.4 to 2.0 mg per day (for a 70 kg human) have been
suggested by various authors (as reviewed by Phillips and Odgers,
1982) for total parenteral nutrition.
As shown in Table 20, the minerals and trace elements are
available either separately or in combined mineral and trace
element modules. Separate NUTRISOURCE enteral modules are
formulated for use with intact protein and with synthetic amino
acids, because intact protein has a higher natural mineral
content. Thus, the mineral levels added to the module for use
with amino acids (as the protein source) must be higher. These
mineral and trace element amounts correspond closely to the
47
requirement levels listed in Tables 5 and 6. The module for use
with intact protein contains lower levels of the electrolytes,
but the same levels of trace elements. LyphoMed, Inc. produces a
module M.T.E.-5, containing small doses of copper, chromium,
manganese, selenium, and zinc, bulk solutions of various
electrolytes (RAP or Rapid Additive Pak), and single element
modules, such as Iodopen (iodine), Molypen (molybdenum), and
Selepen (selenium). These modules are for parenteral use. A
parenteral iron module (Imferon) is produced by Merrell Dow and
other companies (.Physician's Desk Reference, 1984).
Osmolalities
As Table 21 indicates, the solutions with the highest
osmolarities or osmolalities are the more concentrated synthetic
amino acids (10% Travasol, i000 mOsm per liter), the carbohydrate
modules (Polycose, 850 mOsm per kg), and the complete CDD's with
flavorings added (595 to 723 mOsm per kg). Precision Isotonic, a
polymeric CDD, has an osmolality of 300 mOsm per kg. The
monomeric CDD's (Flexical, Vital, and Vivonex) are more
chemically defined with lower molecular weight substances and
have higher osmolalities as a result (460 to 550 mOsm per kg
unflavored). Other CDD's in Table 21 which are approximately
isotonic are 10% Intralipid (280 mOsm per kg), 5% dextrose (278
mOsm per kg), and the single trace element modules--Chrometrace,
Coppertrace, Mangatrace, and Zinctrace (300 mOsm per liter).
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List of Products Cited
The final table (22) includes a list of the modular and
complete CDD's discussed in this chapter. The names and
locations of the manufacturers are also given. The companies
producing CDD's should be consulted for more complete information
and for updated formulations.
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Table 7
Carbohydrates in CDD's
A. Complete Enteral Diets
Flexicall-3 Vivonexl-3,5 Vital 4,5 Precisi°n6isotonic
% of Total kcal
as carbohydrate 61.0 90.5 74.0 60.0
Total grams car- 152.5 230.6 188.0 150.0
bohydrate per
i000 kcal
Carbohydrate Sucrose Glucose 83.2% Sucrose
sources oligo- Glucose
sac- polymers
Oligo- char- (oligo- Maltodextrin
sac- ides and poly-
char- sacchar-
ides ides)
from hy-
drolyzed
corn
Citrate starch Citrate
16. 8%
Sucrose
Lactose
(1.7 mg/
i000 kcal)
Flavors Unflavored Vivonex Fla- Preflav- Preflavored
vor Packets ored orange or
(lemon-lime, vanilla vanilla
orange-pine- or add
apple, Vari-
strawberry, Flavors
or vanilla Flavor
Pacs
(orange,
cherry,
lemon,
pecan, or
straw-
berry)
5O
Table 7 (continued)
Flexicall-3 Vivonexl-3,5 Vital4,5 Precisi°n6isotonic
Flavor ingre-
dients
(nonnutritive) None Artificial Artifi- Artificial
flavors cial and and natural
and colors natural flavors
Citric acid flavors Citric acid
Dextrose (produce
Saccharin no signi-
Silicon ficant
dioxide change in
(adds about the nutri-
8-9 kcal tional
carbohy- status)
drate)
References:
i. Bloch and Shils, 1980
2. Young et al., 1975
3. Young et al., 1982
4. Vital High Nitrogen, 1981
5. Physician's Desk Reference, 1984
6. Sandoz Nutrition, 1984
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Table 8
Carbohydrates in CDD's
B. Modular Carbohydrate Solutions
1
Parenteral
Carbohydrate source Glucose (dextrose) as glucose monohydrate
Concentrations 10% (isotonic): i0 g glucose/100 ml water
50% (hypertonic): 50 g glucose/100 ml
water
2,3,4Enteral
5
Polycose Liquid Moducal
Carbohydrate source(s) Glucose oligosac- Maltodextrin
charides (glucose
polymers
mainly;
some glucose,
maltose, and
isomaltose)
Total carbohydrate 50 g/100 ml 95 g/100 g
Polycose Moducal
Minerals/electrolytes
(maximum level) per i00 ml: per I00 g:
Chloride 140 mg 170 mg
Potassium 6 mg 5 mg
Sodium 70 mg 70 mg
Calcium 20 mg not listed
Phosphorus 3 mg " "
References:
I. Shils, 1980
2. Bloch and Shils, 1980
3. Physician's Desk Reference, 1984
4. Smith and Heymsfield, 1983
5. Mead Johnson & Company, 1984
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Table 9
Major Fat Components in CDD's
A. Complete Enteral Diets
Flexicall-3 Precision4-5 ,Isotonzc Vitall,3-6 Vivonexl-3 6
Major fat Soybean Soybean Safflower Safflower
source(s) oil oil oil oil
MCT oil 7 MCT oil 7
% of Total 30 28 9.3 1.3
kcal as Fat
% of Total i0 4.5 7.0 1
kcal as
Essential
Fatty Acids
Total g 34 31 10.8 1.45
Fat/1000
kcal
Emulsifiers Soy lecithin Mono- and di- Soy leci- Not listed
and other glycerides thin
additives Carrageenan Mono- and
BHA diglycerides
References:
i. Bloch and Shils, 1980
2. Young et al., 1975
3. Young et al., 1982
4. Physician's Desk Reference, 1984
5. Sandoz Nutrition, 1984
6. Vital High Nitroqen, 1981
7. Medium Chain Triglyceride oil
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Table i0
Major Fat Components in CDD's
B. Modular Fat Emulsions
MCT (Medium
Chain Tri-
intralipidl_ 4 Microlipidl, 5 glyceride)oill,5'6
Major fat Soybean oil 74% Linoleic Fractionated
source(s) (contains acid, 44 g/ coconut oil
vitamin E), 120 ml (contains fatty
100-200 g/ Other unsatu- acids of 6-10
liter rated fatty carbons),
acids 93.3 g fat/
i00 ml
Route of admin- IV Enteral Enteral
istration
Emulsifiers Egg-yolk phos- Soy lecithin --
pholipids,
12 g/liter
Other additives
Glycerol (to make 22.5 g/liter ....
it isotonic with
blood)
Amount of fat in
emulsion 10-20% 50% 93.3%
4Trace elements Not listed Not listed
Zinc 33-46 mcg/liter
Copper 20-28 "
Chromium 0.9 "
Iron <100 "
References:
i. Bloch and Shils, 1980
2. Phillips and Odgers, 1982
3. Shenkin and Wretlind, 1979
4. Shils, 1980
5. Smith and Heymsfield, 1983
6. Mead Johnson & Company, 1984
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Table ii
Major Fat Components in CDD's
C. Fatty Acids in CDD Fat Sources
Medium Chain
Triglyceride Safflower Soybean.
Oil1,2 OilI Oil±
Fatty acids, essential
(polyunsaturated)
Linoleic -- 77.0% 54.27%
Linolenic .... 7.81%
Arachidonic ......
Fatty acids, non-
essential
Monounsaturated
Oleic -- 13.0% 26.41%
Palmitoleic .... 0.026%
Saturated
Palmitic -- 7.0% 9.18%
Myristic .... 0.035%
Stearic -- 2.5% 2.87%
Arachidic .... 0.12%
Behenic .... 0.059%
6-10 carbon
fatty acids
(saturated):
<8 carbons 6%
8 carbons 67%
i0 carbons 23%
>i0 carbons 4%
References:
i. Phillips and Odgers, 1982
2. Physician's Desk Reference for Nonprescription Drugs, 1982
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Table 12
Proteins in CDD's
A. Complete Enteral Diets
Precision.
Flexical I-3 Isotonic 4 Vital 1'3,5,6 Vivonex I-3,6
% of Total
kcal as 9.0 12 16.7 8.2
protein
Total grams
protein per
i000 kcal 26.4 30 41.7 20.6
Protein Hydrolyzed Egg albumin 87% Partially Crystalline
sources casein (pasteurized hydrolyzed amino acids
(amino acids, egg white proteins (soy, (synthetic)
small pep- solids) whey, meat) as
tides) small peptides
13% essential
amino acids
References:
i. Bloch and Shils, 1980
2. Young et al., 1975
3. Young et al., 1982
4. Sandoz Nutrition, 1984
5. Vital High Nitrogen, 1981
6. Physician's Desk Reference, 1984
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Table 13
Proteins in CDD's
B. Modular Protein Solutions
Pro MixI'2 CasecI-4 Travasol5'6 Freamine III5
(enteral; (enteral; (8.5%; (8.5%;
dry) dry) parenteral) parenteral)
Protein amount 227 g/ 237.6 g/ 85 g/ 85 g/
i000 kcal; i000 kcal; i000 ml i000 ml
88 g/ 88 g/100 g solution solution
100 g Casec
Pro Mix
Protein Whey Calcium Crystalline Crystalline
source (intact caseinate amino acids amino acids
protein) (intact pro-
tein)
Kcal/concen- i000 kcal/ i000 kcal/ 8.5 g/100 ml 8.5 g/100 ml
tration 284 g 270 g Casec; (5.5% and 10% (10% also
Pro Mix; 370 kcal/ also avail- available)
360 kcal/ i00 g Casec able)
i00 g
Pro Mix
Other nutrients
Carbohydrate 22.7 g/ 0 0 0
i000 kcal
Fat 0 2 g/100 g 0 0
Casec
Minerals/ mEq/1000 per i00 g
Electrolytes kcal: Casec:
Sodium 18.52 150 mg 70mEq/liter Available
with or with-
Potassium 116.51 i0 mg 60mEq/liter out electro-
lytes
Magnesium Not listed Not listed 10mEq/liter
Chloride " " i0 mg 70mEq/liter
(also avail-
able with-
out elec-
trolytes)
Calcium " " 1.6 g Not listed
Phosphorus " " 0.8 g see next page
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Table 13 (continued)
Pro MixI'2 CasecI-4 Travasol5'6 Freamine III5
Other addi-
tives
Acetate (as Not listed Not listed 5.94 g/liter Not listed
sodium ace- (sodium
tate and acetate);
acetic acid 135 mEq/liter
for pH ad- (acetate)
justment)
Sodium bisul- Not listed Not listed 3 mEq/liter Not listed
fite (as sta-
bilizer)
Phosphate Not listed see previous 60 mEq/liter Not listed
page
References:
i. Bloch and Shils, 1980
2. Smith and Heymsfield, 1983
3. Mead Johnson & Company, 1984
4. Physician's Desk Reference for Nonprescription Drugs, 1982
5. Phillips and Odgers, 1982
6. Physician's Desk Reference, 1983
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Table 14
Amino Acids in CDD's
A. Complete Enteral Diets
Flexicall,2 Precisi°n3 ,Isotonic Vital2,4 5 vivonexl,5
Total protein 26.4 g/1000 30 g/1000 41.7 g/1000 20.6 g/1000
kcal kcal kcal kcal
Essential amino
acids (g/1000 kcal)
Histidine 0.705 0.669 1.0842 0.455
Isoleucine 1.425 2.000 1.9182 0.937
Leucine 2.410 2.670 3.3360 1.483
Lysine 2.015 1.812 2.2101 1.115
Methionine 1.060 1.209 1.5012(ref.6) 0.960
Phenylalanine 1.120 1.941 3.4611(ref.7) 1.067
Threonine 1.095 1.335 1.5846 0.937
Tryptophan 0.355 0.477 0.4587 0.290
Valine 1.770 2.352 2.3352 1.034
% of Total pro-
tein 45 45 40 40
Nonessential
amino acids (g/1000 kcal)
Alanine 0.845 2.289 see ref.8 0.999
Arginine 0.935 1.782 " 1.827
Cystine 0.i00 0.732 With methionine 0
Glutamic acid 5.485 4.260 see ref.8 0
Glycine 0.560 1.146 " 1.629
Proline 2.555 1.146 " 1.335
Serine 1.490 2.385 " 0.688
Tyrosine 0.590 1.272 With phenylalanine 0.194
Aspartic acid 1.895 2.385 see ref.8 2.132
Glutamine 0 0 " 3.516
% of Total pro-
tein 55 55 60 60
References:
i. Young et al., 1975
2. Young et al., 1982
3. Sandoz Nutrition, 1984
4. Vital High Nitrogen, 1981
5. Physician's Desk Reference, 1984
6. Total sulfur-containing amino acids (methionine and cystine)
7. Aromatic amino acids (phenylalanine and tyrosine)
8. 13% free amino acids; 87% of protein as small peptides; amounts of
individual amino acids not specified
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Table 15
Amino Acids in CDD's
B. Modular Protein Solutions
Pro Mix I Casec I Freamine III 2 Travasol 8.5% 3
enteral: enteral: parenteral: parenteral:
Total protein 88 g/100 g 88 g/100 g 101.5 g/ 8.404 g/
Pro Mix Casec 16 g nitrogen i00 ml
(N)
Essential amino g/100 g of the module: g/16 g N (i00 g/100 g/
acids g protein): ml: liter:
Histidine 2.5 2.76 2.96 0.372 3.72
Isoleucine 5.8 5.01 7.26 0.406 4.06
Leucine 12.8 8.8 9.47 0.526 5.26
Lysine 10.6 7.51 7.63 0.394 3.94
Methionine 3.7 2.5 5.54 0.492 4.92
Phenylalanine 4.3 4.83 5.90 0.526 5.26
Threonine 5.8 3.63 4.18 0.356 3.56
Tryptophan 2.5 1.12 1.60 0.152 1.52
Valine 6.1 6.3 6.89 0.390 3.90
Nonessential
amino acids
Alanine 5.5 3.28 7.38 1.760 17.60
Arginine 3.5 3.54 9.96 0.880 8.80
Cysteine In cystine In cystine In cystine 0 0
Cystine 4.1 0.26 <0.25 0 0
Glutamic acid 18.2 21.06 0 0 0
Glycine 2.3 1.73 14.64 1.760 17.60
Proline 6.2 10.27 11.69 0.356 3.56
Serine 5.1 4.4 6.15 0 0
Tyrosine 4.1 5.01 0 0.034 0.34
References:
i. Smith and Heymsfield, 1983
2. Phillips and Odgers, 1982
3. Block and Shils, 1980
60
Table 16
Vitamins in Complete Enteral CDD's
Precision_
FlexicalI'2 isotonic3 Vital2,4,5 Vivonex2,5
per i000 per i000 per i000 per i000
kcal: kcal: kcal: kcal:
Water-soluble
B complex
Thiamin (BI) 2.5 mg 1.3 mg 1.0 mg 0.8 mg
Riboflavin (B2) 2.2 mg 1.7 mg 1.13 mg 0.9 mg
Pyridoxine (B6) 2.5 mg 2.0 mg 1.47 mg I.i mg
BI2 7.5 mcg 4.0 mcg 4.0 mcg 3.3 mcg
Folacin 200.0 mcg 270.0 mcg 266.7 mcg 222.2 mcg
Niacin 25 mg 13.3 mg 13.3 mg ii.i mg
(nicotinic
acid and nico-
tinamide)
Pantothenic 12.5 mg 6.7 mg 6.7 mg 5.6 mg
acid
Biotin 150 mcg 200 mcg 200 mcg 170 mcg
Inositol 0 0 0 0
C (ascorbic 150 mg 60 mg 60 mg 33.3 mg
acid)
Choline 250.0 mg 66.7 mg 133.3 mg 40.9
Fat-soluble
A 2500 IU 3333 IU 3333 IU 2778 IU
D 200 IU 266.7 IU 266.7 IU 222 IU
E 23 IU 20 IU 40 IU 17 IU
K 125 mcg 67 mcg 186.7 mcg 37 mcg
(as KI)
References:
I. Young et al., 1975
2. Young et al., 1982
3. Sandoz Nutrition, 1984
4. Vital High Nitrogen, 1981
5. Physician's Desk Reference, 1984
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Table 17
Vitamins in Modular CDD's
Berocca
NUTRISOURCE1 Parenteral2
Vitamins Nutrition M.V.C. 9+32-4
Complete daily Complete daily Complete daily
enteral dose/ IV dose/2 ml IV dose/10 ml
10 g powder solution solution
Water-soluble
B complex
Thiamin (BI) 1.4 mg 3.0 mg 3.0 mg
Riboflavin (B2) 1.6 mg 3.6 mg 3.6 mg
Pyridoxine (B6) 2.2 mg 4.0 mg 4.0 mg
BI2 3.0 mg 5.0 mcg 5.0 mcg
Folacin
(folic acid) 400 mcg 400 mcg 400 mcg
Niacin
(nicotinic
acid and nico-
tinamide) 18.0 mg 40.0 mg 40.0 mg
Pantothenic
acid 5.5 mg 15.0 mg 15.0 mg
Biotin 150 mcg 60 mcg 60 mcg
Inositol 0 0 0
C (ascorbic acid) 60.0 mg i00.0 mg I00.0 mg
Choline 100.0 mg 0 0
Fat-soluble
A 5000 IU 3300 IU5 3300 IU5
D 200 IU 200 IU 200 IU
E i0 IU i0 IU i0 IU
K 70 mcg 06 06
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Table 17 (continued)
Berocca
NUTRISOURCE 1 Parenteral 2
Vitamins Nutrition M.V.C. 9+32-4
Additives
Carrier maltodextrin 0 0
(9 g carbo-
hydrate)
pH correction 0 Sodium hy- Sodium hy-
droxide droxide
Citric acid Monobasic
potassium
phosphate
Benzyl al-
cohol
Solubilizer 0 Polyoxy- Polysor-
ethylated bate-20
vegetable oil
Antioxidants Not listed Not listed BHA
BHT
Stabilizers and
preservatives Not listed Propylene Propylene
glycol glycol
Gentisic acid Gentisic acid
Ethanolamide Ethanolamide
Ethyl alcohol
Sodium citrate
Benzyl alcohol
Disodium
edetate
References:
i. NUTRISOURCE Technical Information Manual, 1982
2. Physician's Desk Reference, 1984
3. Feroz et al., 1982
4. M.V.I.-12 (Armour Pharmaceutical Company) is almost identical
5. Recommended for parenteral route (American Medical Association,
1979b)
6. 2-4 mg once per week recommended if no anticoagulant therapy is
being given (American Medical Association, 1979b)
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Table 18
Minerals/Electrolytes in Complete Enteral CDD's
Precision_
FlexicalI'2 isotonic3 Vital4,5 Vivonex2,5
mg/1000 kcal
Calcium 600 666.7 666.7 556
Chlorine (as 1000 1070 900 722
chloride)
Magnesium 200 267 266.7 222
Phosphorus 500 666.7 666.7 556
Potassium 1250 i000 1333.3 1172
Sodium 350 800 466.7 468
References:
i. Young et al., 1975
2. Young et al., 1982
3. Sandoz Nutrition, 1984
4. Vital High Nitrogen, 1981
5. Physician's Desk Reference, 1984
64
Table 19
Essential Trace Elements (Per I000 kcal)
in Complete CDD's
Flexicall,2 Precisign3 1,2,5Isotonlc Vital 2'4'5 vivonex
Cobalt 6 ........
Copper (mg) 1.0 1.3 1.33 i.i
Chromium (mcg) 0 I00 0 28
Fluorine as 0 0 0 0
(fluoride)
Iodine (mcg) 75.0 I00 i00.0 83.3
Iron (mg) 9.0 12 12.0 i0.0
Manganese (mg) 2.5 2.7 2.5 1.6
Molybdenum (mcg) 0 200 0 83
Selenium (mcg) 0 66.7 0 83
Sulfur 7 ........
Zinc (mg) i0 i0 i0 8.3
References:
i. Young et al., 1975
2. Young et al., 1982
3. Sandoz Nutrition, 1984
4. Vital High Nitrogen, 1981
5. Physician's Desk Reference, 1984
6. Part of vitamin BI2
7. Part of the amino acids, cysteine and methionine
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Table 20
Minerals and Trace Elements in Modular CDD's
NUTRISOURCE NUTRISOURCE
Minerals for Minerals for RAP(Rapid
Protein 1 Amino Acid Additive 2
Formulas Formulas I M.T.E.-52 Pak)
Complete daily Complete daily Parenteral Parenteral
enteral dose/ enteral dose/ trace ele- electro-
24 g powder: 24 g powder: ments: lyres:
A. Mixtures
Calcium 0.65 g 0.80 g 0 Calcium
Chlorine gluconate
(chloride) 1.8 g 2.0 g 0 Potassium
Magnesium 0.35 g 0.35 g 0 chloride,
Phosphorus 0.65 g 0.80 g 0 etc.
Potassium 1.75 g 2.2 g 0
Sodium 1.0 g 1.3 g 0
Copper 2.0 mg 2.0 mg 0.4 mg/ml
Chromium 125 mcg 125 mcg 4 mcg/ml
Fluorine 0 0 0
Iodine 150 mcg 150 mcg See below
Iron 18.0 mg 18.0 mg See below
Manganese 4.0 mg 4.0 mg 0.i mg/ml
Molybdenum 325 mcg 325 mcg See below
Selenium 125 mcg 125 mcg 20 mcg/ml
zinc 15.0 mg 15.0 mg 1 mg/ml
Additive
Carrier maltodextrin maltodextrin ....
(6 g carbo- (3 g carbo-
hydrate) hydrate)
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Table 20 (continued)
B. Single elements
(parenteral solutions):
Chrometrace 4 mcg chromium/ml3
(as chromic chloride)
Coppertrace 0.4 mg copper/ml3
(as cupric chloride)
Mangatrace 0.i mg manganese/ml3
(as manganese chloride)
Zinctrace 1 mg zinc/ml3
(as zinc chloride)
Iodopen i00 mcg iodine/ml2
(as sodium iodide)
Molypen 25 mcg molybdenum/ml2
(as ammonium molybdate)
Selepen 40 mcg selenium/ml2
(as selenious acid)
Imferon - iron dextran 50 mg iron/ml3
complex (as ferric hydro-
xide and dextran in sodium
chloride solution)
References:
i. NUTRISOURCE Technical Information Manual, 1982; NUTRISOURCE
Minerals also available in electrolyte-restricted formulations
2. LyphoMed, Inc., 1983
3. Physician's Desk Reference, 1984
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Table 21
Osmolarities/Osmolalities of CDD's
1 1
Osmolarity Osmolality
mOsm/liter water: mOsm/kg water:
A. Complete Oral CDD's
Flexical 723 5503,4
(flavored 2)
723
(flavored 5)
Precision Isotonic 3006
Vital High Nitrogen 460
(unflavored 7)
475-490
(flavored 7)
Standard Vivonex 595-600
(flavored 8)
550
(unflavored 8)
B. Modular CDD's
Intralipid 10%: 280 9
20%: 330
Moducal 72510
Polycose 8508'10
9
Dextrose (glucose)
5% 278
10% 523
20% 1250
30% 2100
50% 3800
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Table 21 (continued)
Osmolarity I Osmolality 1
m0sm/liter water: mOsm/kg water:
Travaso112
2.75% 425 (with electrolytes)
10% i000 (without electrolytes)
Chrometrace 3008
8
Coppertrace 300
Mangatrace 3008
8
Zinctrace 300
References:
i. Listed as reported by the source referenced: milliosmoles/liter
water = milliosmoles/kilogram (kg) water (i liter pure water
weighs 1 kg)
2. Koretz and Meyer, 1980
3. Bloch and Shils, 1980
4. Young et al., 1982
5. Young et al., 1975
6. Sandoz Nutrition, 1984
7. Vital High Nitrogen, 1981
8. Physician's Desk Reference, 1984
9. Shenkin and Wretlind, 1979
i0. Smith and Heymsfield, 1983
ii. Phillips and Odgers, 1982
12. Physician's Desk Reference, 1983
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Table 22
List of CDD's
Included in Chapter II
CDD Type Manufacturer
A. Complete
Flexical* Monomeric Mead Johnson & Company
Nutritional Division
Evansville, IN
Precision Isotonic Polymeric Sandoz Nutrition
Minneapolis, MN
Standard Vivonex Monomeric Norwich-Eaton Laboratories
Norwich, NY
Vital High Nitrogen Monomeric Ross Laboratories
Columbus, OH
B. Modular
Moducal Carbohydrate Mead Johnson & Company
source (enteral) Nutritional Division
Evansville, IN
Polycose Carbohydrate Ross Laboratories
source (enteral) Columbus, OH
Dextrose IV Carbohydrate Abbot Pharmaceuticals
solutions source (IV) North Chicago, IL
American McGaw
Division of Hospital
Supply Corp.
Irvine, CA
Cutter Laboratories
Energyville, CA
MCT (medium Fat source Mead Johnson & Company
chain triglyceride) (enteral) Nutritional Division
Oil Evansville, IN
Intralipid Fat source Vitrum
(IV) Stockholm, Sweden
7O
Table 22 (continued)
CDD Typ____ee Manufacturer
Microlipid Fat source Biosearch Medical Products
(enteral) Summerville, NJ
(formerly produced by
Organon Inc.
West Orange, NJ)
Casec Protein Mead Johnson & Company
(enteral) Nutritional Division
Evansville, IN
Pro Mix Protein Navaco Industries
(enteral) Phoenix, AZ
Freamine III Amino acids American McGaw
(IV) Division of Hospital
Supply Corp.
Irvine, CA
Travasol Amino acids Travenol Laboratories, Inc.
(IV) Parenteral Products
Deerfield, IL
NUTRISOURCE Vitamins; Sandoz Nutrition
Minerals with Minneapolis, MN
trace elements
(enteral)
Berocca Parenteral Multivitamins Roche Laboratories
Nutrition (IV) Division of Hoffmann-
LaRoche Inc.
Nutley, NJ
M.V.C. 9+3 Multivitamins LyphoMed, Inc.
(Multivitamin (IV) Chicago, IL
Concentrate for
Infusion)
RAP Electrolytes ,,
(IV)
M.T.E.-5 Trace elements ,,
(IV)
Iodopen Iodine (IV) "
Molypen Molybdenum (IV) "
Selepen Selenium (IV) ',
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Table 22 (continued)
CDD Type Manufacturer
Chrometrace; Trace elements Armour Pharmaceutical Company
Coppertrace; Tarrytown, NY
Mangatrace;
Zinctrace
M.V.I.-12 Multivitamins "
(IV)
Imferon Iron source (IV) Merrell Dow Pharmaceuticals
Inc.
Cincinnati, OH
*No longer available (reformulated as Criticare HN)
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Summary
Human adults require fluid; energy; protein containing 8 to
9 essential amino acids; carbohydrate; fat containing the
essential fatty acid, linoleic acid; about 13 vitamins; 6
minerals and electrolytes; and about ii trace elements in the
daily diet. These represent the minimum number of dietary
nutrients humans need to be healthy. Additional vitamins and
trace elements may be added as more is learned about human
nutrition.
Chemically defined diets (CDD's) in this report include
liquid diets that are formulated so that the components can be
quantified and reproduced to a much greater degree than a
typical, solid food diet. Various types of CDD's have been
developed for oral, tube, or intravenous administration,
depending on the degree of function of the patient's
gastrointestinal system. The relative proportions of fat,
carbohydrate, and protein can be adjusted in a CDD, and the
specific types of fats, carbohydrates, and proteins vary. Both
nutritionally complete CDD's and modular CDD's containing a
single nutrient or a combination of nutrients, are available.
The compositions of representative CDD's are shown in Tables
7-22. Experience with the administration of various types of
CDD's in humans and laboratory animals is described in Chapter
III.
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CHAPTER III
CLINICAL AND EXPERIMENTAL USE OF
CHEMICALLY DEFINED DIETS
CDD's have been used therapeutically in seriously ill
patients, in nutritional studies in healthy humans, and in
laboratory animals. Most of the work has been in connection with
the therapeutic application of special diets. Relevant studies
for each application of CDD's are summarized below. The emphasis
in these summaries is on the nutritional knowledge that has been
gained from experience with various types of formulated diets.
Short- and long-term effects of these diets are also outlined.
Clinical Studies
The use of various types of formulated liquid diets has been
increasing. There is a medical journal devoted entirely to the
subject (Journal of Parenteral and Enteral Nutrition). Although
the majority of CDD's are used for a few weeks, some patients
need to be fed these diets on a long-term basis. A growing
number of people, who can never return to solid food, are being
discharged on home TPN (total parenteral nutrition) via a
permanently implanted catheter in a neck or shoulder vein. From
1970 to 1977 at least 400 patients were placed on home TPN, and
an international organization to record data on home TPN patients
has been established (Shils, 1980). This organization, the
75
Registry of Patients on Home Parenteral Nutrition at the New York
Academy of Sciences (2 East 103 St., New York, NY 10029),
estimates that 1500 or more people in the United States have
begun home TPN since about 1973 (Howard et al., 1983).
There are many medical reasons for using various types of
CDD's either through peripheral or central veins (parenteral) or
via the gastrointestinal (GI) tract (enteral). The GI tract can
be reached orally, when the patient simply drinks the diet, by
nasogastric tube feeding, or by a catheter surgically implanted
in the stomach or small intestine. A combination of parenteral
and enteral nutritional support may also be used. The use of a
central vein for all nutrients (TPN) is to be undertaken only
when the other methods cannot meet the patient's needs. This is
because the procedures for implanting the catheter in a central
vein are tricky and uncomfortable and because there can be
serious complications.
Phillips and Odgers (1982) report that the conditions most
often requiring parenteral nutrition are inflammatory bowel
diseases, enterocutaneous fistulas, and before and after various
abdominal operations. The many conditions that may require some
type of CDD for nutritional support are listed in Table 23.
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TABLE 23
Clinical Applications of CDD's
i. Gastrointestinal (GI) Problems
fistulas*
malabsorption
short bowel syndrome
inflammatory bowel disease*
(Crohn's disease, ulcerative colitis)
obstruction in GI tract
liver diseases
pancreatitis
congenital defects
2. Hypermetabolic States
traumatic injuries
severe burns
surgery
3. Prolonged Coma
4. Preparation for Diagnostic Procedures
of the GI Tract
5. Pre- and Postoperative Management
abdominal surgery*
colon and rectum operations
head and neck surgery
6. Persistent Nausea/Vomiting
7. Anorexia
8. Food Allergies (diagnosis/treatment)
9. PKU (phenylketonuria)--to maintain
special diet
i0. Mental Retardation--to facilitate
nursing care
ii. Cancer
12. Transition from TPN to Solid Food
(enteral CDD's)
*most common reasons for use of parenteral nutrition
References:
i. Sandoz Nutrition, 1984
2. Heymsfield, et al., 1979
3. Howard et al., 1983
4. Koretz and Meyer, 1980
5. Phillips and Odgers, 1982
6. Russell, 1975
7. Shils, 1980
8. Voitk, 1975
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The value of using enteral CDD's in many of the conditions in
Table 23 has been questioned by Koretz and Meyer (1980) on the
grounds that very few controlled studies comparing enteral CDD's
with solid food have been conducted. The authors conclude that
the benefits of CDD's over regular solid (or blenderized) food
need to be substantiated, due to the high costs, unpleasant
tastes, and side effects of these special diets. Another
controversy concerns when to use enteral versus parenteral diets.
Heymsfield et al. (1979) report that, at least in their
experience, a large number of patients on TPN could tolerate
either enteral diets or combinations of enteral and parenteral.
More well-controlled clinical trials might clarify this.
However, as Randall (1984) points out, improved studies may not
always be feasible, due to the number of subjects needed for
statistical purposes, the great expense involved, and the large
number of CDD's being developed.
Due to the life threatening nature of the patients'
conditions and the technical complexity of (TPN), more clinical
attention has been given to this type of CDD in the medical
field. Recently, there has been increasing interest in enteral
CDD's, because of the greater medical risks associated with TPN.
The physiological and psychological effects of CDD's are
summarized below. Mechanical problems in the administration of
CDD's and potential drug interactions with CDD ingredients are
covered briefly.
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Medical Complications
The major categories of complications associated with CDD's
are similar, regardless of the route of administration. These
include mechanical and other problems related to administering
the diets, gastrointestinal side effects and changes,
physiological imbalances that frequently involve either nutrient
excess or deficiency (Cataldi-Betcher et al., 1983), and
psychological problems. These complications are summarized in
Table 24.
Complications that are unique to TPN involve the central
veinous catheter for the most part and special problems in
providing the correct balance of nutrients intravenously, as
discussed in Chapter II. Hazards of the catheter include
infection from contamination of the catheter as well as
phlebitis, thrombosis, pneumothorax, and punctured blood vessels
from incorrect catheter position (Shils, 1980).
Nasogastric feeding is the most common route for tube-fed
enteral CDD's (Cataldi-Betcher et al., 1983). A serious
mechanical complication that is unique to enteral CDD's
administered by nasogastric tube is aspiration or regurgitation
of the stomach contents. The patient can choke to death, because
some of the fluid inevitably reaches the lungs (aspiration
pneumonia). Some tubes can damage the throat and esophagus
(Heymsfield et al., 1979). The problem of aspiration can be
avoided by surgically attaching the feeding tube directly to
various points in the GI tract (such as the stomach or jejunum).
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Other risks are associated with these surgical routes (Randall,
1984).
Other mechanical problems with both TPN and enteral CDD's are
blockage of the catheters or tubes, due to thickening of the
nutrient solutions. The ingredients must be mixed correctly to
avoid interactions, either among the CDD constitutents or with
other medications. Antibiotics, nutrients, antipsychotic drugs,
cold medicines and other agents (that might be given to patients
in enteral feeding solutions) were mixed with several common
enteral diets in the laboratory by Cutie et al. (1983).
Pharmaceutical syrups were associated with frequent incompati-
bility reactions. Other potential drug interactions include
adverse effects on stability, bioavailability, and effectiveness.
Contaminated nutrient solutions, as well as feeding tubes or
catheters, can lead to serious, life-threatening infections in
TPN or GI disturbances in enteral or oral CDD's (Cataldi-Betcher
et al., 1983; Jeejeebhoy et al., 1976). The risk of a systemic
infection has been a major complication of TPN (Voitk, 1975).
A review of the 12-month medical records of 253 patients on
tube-fed (various entry routes for the tubes) CDD's showed that
52% of the complications (in 6.2% of the patients) were
gastrointestinal, mechanical problems occurred in 3.5% of the
patients (aspiration pneumonia in 0.8% of the patients), and
metabolic complications in 2% of the patients. Diarrhea was the
most common GI complaint. Other complaints included vomiting, GI
bleeding, and incomplete or retarded emptying of the stomach.
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Besides contaminated solutions, other factors contributing to GI
upsets during CDD intake are high velocity feeding rates, feeding
large quantities at once, highly concentrated (high osmolality)
solutions, and too little bulk in the very low residue diets
(Cataldi-Betcher et al., 1983). Other GI problems reported
include nausea, halitosis, and abdominal cramps (Koretz and
Meyer, 1980). It is somewhat ironic that some of the medical
conditions that warrant use of CDD's may be aggravated by some
aspect of the CDD itself. This points to the fact that altering
a normal, solid food diet is a complex precedure, and that
patient response to a certain CDD is subject to considerable
individual variation. Although Randall (1984) states that only a
small number of published studies have been done on the effects
of enteral CDD's in patients, his clinical experience has shown
that most patients with 60 cm or more of small intestine can
tolerate these diets.
A number of investigators have looked at the effects of CDD's
on the anatomy and physiology of the GI tract. Most of the
studies dealing with the effects of CDD's on the GI system have
been in laboratory animals, which are discussed later in this
chapter. The results are somewhat conflicting; however, some of
the major findings will be summarized. Because the digestive
system is bypassed, one might expect some reduction in normal GI
functioning during TPN. The presence of food and its chemical
composition in the GI tract stimulate the release of various
digestive system hormones and enzymes, such as from the stomach
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(gastrin and pepsins), duodenum (secretin and cholecystokinin),
pancreas (enzymes, insulin, and glucagon), and liver (bile)
(Vander et al., 1975). Reduced secretions of some of these
hormones and enzymes have been observed during parenteral
nutrition (Phillips and Odgers, 1982; Shenkin and Wretlind,
1979).
Greenberg et al. (1981) investigated the plasma levels of
intestinal hormones in 17 patients with Crohn's disease before,
during, and after TPN therapy. Nine of the patients, who had
been on TPN for an average of 25 days and were deemed ready to
eat solid food, were given test breakfasts during which several
blood samples were collected from 30 minutes before to 3 hours
after. The first test breakfast (orange juice, eggs, toast, and
jam) was given the morning after TPN was discontinued. The
patients then began eating regular meals for an average of 156
days, after which they were given the same test breakfast and
blood samples were collected. Plasma glucose and nine intestinal
hormones (gastrin, motilin, secretin, gastric inhibitory peptide,
pancreatic glucagon, enteroglucagon, insulin, pancreatic
polypeptide, and vasoactive intestinal peptide) were assayed in
the blood samples. No significant differences in hormones were
found except in insulin and enteroglucagon. The peak insulin
response was significantly reduced after the first test meal
following the end of TPN, than following the second test meal
after eating normal meals. Because the glucose increase
following both test meals was similar, there may have been
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peripheral insulin hypersensitivity due to TPN. A significantly
higher peak enteroglucagon level was found following the first
test meal after TPN than after the second test meal. The
enteroglucagon levels were similar before each of the test meals.
The greater response after the first test meal may have been due
to a decrease in the time for food transport through the
intestine, causing nutrient stimulation of the small intestine.
Another study was done in the remaining 8 patients on TPN for an
average of 22 days. Blood samples were taken before TPN was
started, at various points during, and 3 days after TPN was
discontinued. The same intestinal hormones were measured as in
the first study. No significant hormonal fluctuations due to TPN
were detected.
A recent case study by Bivins et al. (1984) was in a TPN
patient with a pancreatic fistula, which enabled the
investigators to collect and measure pancreatic output every 8
hours for 12 days. The output was measured first during dextrose
and saline administration for 3 days, then dextrose and
crystalline amino acids (and safflower oil on the sixth and
eighth days) for the next 6 days, and finally during oral intake
for 3 days. Pancreatic output decreased during parenterai
nutrition, compared with the output when the patient was on solid
food prior to the study, the output remained about the same for
one day on a diet of clear liquids, and a large increase in
pancreatic output occurred on both a high protein oral diet and a
high fat oral diet over the next 2 days. Because the data are
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from only one patient and because some other clinical reports
have shown increased pancreatic secretions in certain cases,
these results should be taken with caution until more research
has been done. Also, individual variations occur with many
physiologic parameters, particularly nutritional/digestive
responses.
In addition to physiological changes in the GI system during
TPN, structural changes have also been reported. These changes
include hypoplasia of the intestinal mucosa (reduced length,
weight, and thickness) and lowered numbers of intestinal microbes
(Shenkin and Wretlind, 1979). The effects on the intestinal
mucosa have been described in more detail by studies in
laboratory animals.
Enteral CDD's might be expected to alter gastrointestinal
functions less drastically than parenteral CDD's. Nevertheless,
a number of changes have been reported. Monomeric CDD's have
been reported to produce lower pancreatic output than polymeric
diets, although others have found increased pancreatic output.
Some studies have also reported reduced microbial populations in
the intestines with enteral CDD's while other studies have found
no effects (Koretz and Meyer, 1980; Winitz et al., 1970b). The
implication of reduced intestinal bacteria is that synthesis of
vitamin K and biotin might also be reduced, and this could create
deficiencies of these vitamins unless the CDD's contain them.
Depending on the diet composition, enteral CDD's produce reduced
fecal output and decreased number of bowel movements (Russell,
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1975).
The effectiveness of an elemental (monomeric) diet (Vivonex
HN) versus a polymeric diet (Clinifeed 400) was assessed in 70
hospital patients, matched for race, age, sex, diagnosis,
nutritional status, etc. (Jones et al., 1983). All 70 patients
had normal GI system functions. In the prospective, 1-year study
each of the 70 patients was randomly assigned to one of the
diets. Thirty-four patients received High Nitrogen Vivonex, and
36 received Clinifeed 400. The Vivonex group was fed for an
average of about 14 days (with a range of i to 35 days), and the
Clinifeed group was fed for an average of about 15 days (with a
range of 2 to 60 days). The effectiveness of the CDD's was
compared on the basis of nutritional status and nitrogen balance,
GI upsets, metabolic problems, and effects on liver enzymes.
There were no clinical differences of major importance between
isonitrogenous and isocaloric doses of the diets. Less nitrogen
was excreted in the polymeric diet group (although not
statistically significant) suggesting slightly better nitrogen
balance. Increased liver enzymes occurred in both groups, but
were within normal limits at the end of the study. The
investigators concluded that less expensive polymeric diets
rather than monomeric diets should be used in patients with
normal GI systems who need nutritional support. In another
study, the use of polymeric instead of monomeric CDD's after
major abdominal operations was also found to be effective by
Riley et al. (1980).
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Physiological imbalances are a potential hazard whenever
CDD's are used, particularly in people with existing health
problems. Water must be given in addition to the enteral CDD
solutions to prevent fluid and electrolyte upsets, such as
dehydration (Russell, 1975). Adverse metabolic reactions
occurred least often in a survey of 253 patients on enteral
CDD's. Only 2% of the patients experienced these problems, which
included hyperkalemia (serum potassium too high), hypokalemia
(serum potassium too low), and hyperosmolality/dehydration.
Various nutrient deficiencies or excesses and other physiological
imbalances seem to bemore frequent during TPN (Cataldi-Betcher,
1983).
Some of the most frequent physiological problems during TPN
include hyperglycemia (excess glucose), hypokalemia (low
potassium), and hypophosphatemia (low phosphate) (Phillips and
Odgers, 1982). Vitamin and trace element deficiencies have been
encountered a great deal in patients on TPN for long periods, as
discussed in Chapter II. These deficiencies may become less
common as more is established about parenteral micronutrient
requirements. Howard et al. (1983) state that parenteral folic
acid requirements may be higher than those for the oral route and
that extreme deficiencies of this vitamin in TPN have been
reported. Although the American Medical Association (1979b)
recommended 0.4 mg per day parenterally (the same as the oral
requirement), the requirement may be higher in some patients.
A vitamin that has not been included in routine TPN solutions
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is biotin. The American Medical Association (1979b) recommends
60 mcg per day IV. Levenson (1983) reported that a patient on
TPN for over 5 months with no biotin developed depression,
threatened suicide, insomnia, vomiting, headaches, gray skin
color, dermatitis, and other symptoms. After 300 mcg biotin
supplements were given for a week, the symptoms were relieved.
Innis and Allardyce (1983) reported 2 patients on TPN for 5 to 6
months, both of whom began experiencing extensive hair loss.
After 2 months of daily biotin, their hair was restored. The
authors stated that severe intestinal diseases or antibiotics can
interfere with intestinal biotin synthesis.
Although knowledge of nutrient requirements can help prevent
many imbalances during nutrition with CDD's, nutrient
requirements vary considerably among individuals. For example,
Thompson and Hodges (1984) surveyed the medical records of TPN
patients to investigate the occurrence of hypophosphatemia. This
complication has been a problem even when phosphate supplements
are given according to published requirements. Urinary phosphate
losses are increased due to hyperglycemia, use of diuretics or
steroids, severe burns, and other conditions, and phosphate doses
may have to be increased in these cases.
Trace metal deficiencies may take many months to develop and
can be associated with severe overt symptoms and/or more subtle
biochemical changes. Kien and Ganther (1983) report a case of
selenium deficiency in a 10-year-old boy on TPN for 1-1/2 years.
Symptoms included unusual white nail beds, recurrent leg muscle
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pains, and elevated liver and skeletal muscle enzymes. Baker et
al. (1983) reported the following biochemical evidence of
selenium deficiency in a patient on TPN for 14 months: low
erythrocyte selenium content, low erythrocyte glutathione
peroxidase (which needs selenium for its activity), and other
biochemical changes.
Chromium deficiency developed in a patient on TPN for 3-1/2
years before chromium became routinely given. Symptoms included
peripheral neuropathy, glucose intolerance, and a 15% weight loss
with the same caloric intake (Jeejeebhoy et al., 1977).
Molybdenum deficiency appeared after another patient was on TPN
for over a year. The severe symptoms were psychological
problems, coma, vomiting, headaches, night blindness, and other
reactions after infusion of a commercial amino acid solution.
Molybdenum is a cofactor for enzymes involved in amino acid
metabolism, and supplements of ammonium molybdate reversed the
symptoms. There are many more examples of nutrient imbalances
caused by CDD's. These types of case studies have made the
refinement of CDD components possible.
Long-term TPN
The first clinical test of TPN was done by Dudrick et al.
(1968) in 30 patients with serious diseases of the GI tract. The
TPN solution included 20% glucose, 5% protein hydrolysate,
electrolytes, vitamins, and trace elements. The patients were
given TPN for i0 to 200 days, and all 30 improved with respect to
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nutritional status and disease stage.
One of the best-documented case studies of a permanent home
TPN patient is by Jeejeebhoy et al. (1973). At time of
publication, the woman had been on TPN for 2-1/2 years and had
made remarkable social and medical adjustments. Her intestines
had been almost completely destroyed due to mesenteric vein
thrombosis in 1970 at age 36, and she spent the first 9 months
after surgery in the hospital. She then began home TPN, after
which her condition has been monitored periodically. The same
catheter was in place for 30 months with no infections, due to
the use of special Millipore filters to prevent solution
contamination. The medical team concluded that a mixture of half
the kcal as lipid and half the kcal as carbohydrate was
preferable to all of the energy requirement from carbohydrate.
They also found that lipid infusions are needed both to supply
essential fatty acids and to prevent fatty liver deposits. Fatty
changes were observed in liver biopsies when carbohydrate alone
was the energy source. These changes were reversed with the
combined lipid and carbohydrate energy sources. Although
periodic nutrient imbalances have been reported for this patient
(Jeejeebhoy et al., 1977), she has been in a fairly healthy state
on home TPN, and this was still the case as of the report by
Shenkin and Wretlind (1979).
Jeejeebhoy et al. (1976) reviewed the case histories of 12
home TPN patients, including the one above. The total time on
TPN varied from 3 months to 3 years. Daily fluid requirements
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were about 3-1/2 liters per patient. Results of a variety of
laboratory tests are tabulated in the review.
Psychological Aspects
Because CDD's represent a total change in diet, they are not
well tolerated by all patients. The monomeric enteral CDD's, in
particular, are reported to have unpleasant tastes and odors,
which are still a problem with the addition of flavoring agents
(Koretz and Meyer, 1980). The synthetic amino acids seem to be
the main contributors to the bad tastes (Smith and Heymsfield,
1983). Nasogastric tube feeding is often required for enteral
CDD's, because the patient is unable to drink enough of the diet
to satisfy nutrient requirements (Heymsfield et al., 1979).
The most extreme therapeutic CDD is TPN, which may be
required on a permanent basis by certain individuals. Those who
are on permanent home TPN can be compared with people on kidney
dialysis--they face significant changes in their lifestyles.
Although the appetite is lowered on TPN (Shenkin and Wretlind,
1979), Malcolm et al. (1980) state that one of the most common
complaints of TPN patients is the obvious one--that they still
miss eating regular food. The appetite reduction is temporary
and returns after TPN is ended. The amount of time these
patients are connected to the TPN solutions may be a few times
per week (partial TPN) or up to 18 hours per day. Psychiatric
problems that have been encountered in long-term TPN patients
include extremely negative body image, psychosomatic ailments,
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family problems, noncompliance with TPN, and in rare cases,
psychotic reactions. Nutritional deficiencies or excesses of
vitamins, trace elements, or amino acids can lead to neurological
disturbances, creating psychological problems such as depression.
Healthy Human Volunteers
NASA and Air Force Studies
As outlined in the introduction to this report, some early
studies on CDD's in the 1960's were sponsored by NASA. The test
subjects were human volunteers and laboratory animals (discussed
in the next section). A liquid diet was tested for 8 days in a
two-person space cabin simulator by Welch (1964). Eight Air
Force volunteers tried the diet, which included toasted soy
protein, powdered skim milk, homogenized oats, and vitamin A.
The subjects also drank orange-grapefruit juice that had dextrin
in it, and they were allowed to eat some hard candy. The diet
was unflavored, and the subjects complained that it lacked taste,
variety, had a bad odor, and that they wanted solid food. The
subjects lost an average of 45 grams body weight per day.
One of the major NASA-sponsored projects to develop oral
CDD's began in 1961: the principal investigator was Milton
Winitz (1962). The main diet included L-amino acids, vitamins,
minerals, linoleic acid as ethyl linoleate, and glucose as the
main energy source. A review of this project (Winitz et al.,
1965) indicates that the diet was tested in hospital patients
with good results. The major test in healthy humans was
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conducted at a prison using 24 male inmates selected from 160
volunteers.
Detailed results of the 10-month study were reported by
Winitz et al. (1970a). The study was conducted from 1963 to 1964
in the California Medical Facility in Vacaville. The 24 inmates
were from 24 to 43 years old. This CDD had been tested mainly in
laboratory animals (predominantly rats). The subjects consumed
several variations of the liquid diet for 25 weeks. Medical data
were also collected for 4 weeks before and 13 weeks after the CDD
test while the subjects were eating normal meals. The CDD was
administered 4 times per day, 3 hours apart. Distilled water was
taken as needed, and the subjects were allowed to drink the
amounts of the CDD that suited them at each of the 4
presentations. Their actual caloric intakes varied from 2300 to
3400 kcal. Fifteen of the original 24 inmates continued to the
end of the study. Six of the volunteers dropped out due to
dislike of the diets. Three others dropped out for reasons
unrelated to the study.
Bowel movements were significantly reduced compared to
experience with normal meals. Weekly urinalyses of the subjects
were within normal limits. Periodic batteries of blood tests
were performed before, during, and after the study. Fasting
blood sugar levels were at the low range of normal for all
subjects and were significantly lower than the levels before the
study or after returning to normal meals. Another alteration
during intake of the CDD was a decrease in serum cholesterol with
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glucose as the carbohydrate source. Cholesterol levels increased
when sucrose was substituted for 25% of the glucose and went down
again after a return to all glucose. Weekly medical checkups
were done and no adverse effects were found. Other tests, such
as electrocardiograms, chest x-rays, eye exams, and dental
reports, were normal. Some subjects experienced halitosis, which
may have happened because less saliva was produced. Weight
losses were observed in all subjects during the first week, which
the investigators stated was due to a loss in the intestinal bulk
present on a solid-food diet. Six initially overweight subjects
lost from 3-1/2 to 24-1/2 pounds by the end of the study. All of
the subjects had normal blood pressures at the beginning of the
study. After several days on the CDD, the systolic and diastolic
blood pressures decreased. Within a week after their return to
regular solid food, the subjects' blood pressures were up to the
initial levels. No degeneration of teeth or gums due to lack of
solid food was observed. The CDD's were deemed nutritionally
acceptable as a result of this study.
Winitz et al. (1970b) conducted several short-term feeding
studies with adult volunteers, both males and females, who were
not institutionalized. The purpose of the studies was to monitor
the effects of CDD's of various types on the populations of
intestinal microorganisms. The populations and the number of
species were rapidly reduced after a few days on the CDD's. The
intestinal microorganisms returned to normal after the subjects
ate regular food again. The changes were more pronounced on
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glucose-based than sucrose-based CDD's in a 43-day study in one
subject.
The Air Force also sponsored projects to develop CDD's in the
1960's, several of which were joint projects with NASA.
Hollender et al. (1965) described one of the CDD's, which
required vitamin/mineral supplements in capsule form. The diet
consisted of sodium caseinate, egg albumin, and other intact
proteins, sucrose, glucose, starch, corn oil, and various
additives and flavoring agents. The various flavored versions
were taste-tested by panels. On a scale of 1 to 9, some of the
liquid CDD's received scores of 6 or more. Vanilla and chocolate
were preferred to strawberry, cherry, coffee, orange, cream soda,
banana, butterscotch, caramel, or coconut. The investigators
noted that the Space Science Board of the National Research
Council had recommended the use of liquid diets for space travel.
Four college males tested a fresh food diet for 30 days and
then a liquid diet for the next 20 days in a study by Katchman et
al. (1967). The subjects were confined to a Controlled Activity
Facility (CAF) for the first 6 days, a Life Support Systems
Evaluator (LSSE, a simulated aerospace environment) for the next
28 days, and then the CAF for the remaining 6 days. The subjects
were under metabolic control during the study. Two of the
subjects wore an unpressurized space suit 8 hours per day for the
28 days in the LSSE. The flavors of the liquid diet were varied
from cherry to vanilla, chocolate, and strawberry. The subjects
disliked the monotony of the liquid diet versus the fresh foods
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(various meats, bread and butter, fresh lettuce with oil and
vinegar, fruits, and tea with sugar). The 2444 kcal liquid diet
(approximately 204 g carbohydrate, 70 g protein, 167 g fat plus
supplements of vitamins and minerals) was similar in chemical
composition to the fresh food diet. A number of laboratory tests
on urine, feces, blood, _ heart rate, and blood pressure were found
to be within normal limits. The liquid diet had a 5.5% lower
overall degree of digestibility than the solid diet, and weight
losses were produced in 2 subjects. A negative balance state was
found for calcium, potassium, and phosphorus. The liquid diet
increased the frequency of bowel movements compared with the
fresh food.
The above study was repeated with another group of 4 college
males (Katchman et al., 1970). All 4 subjects wore the space
suits. This time the liquid diet had 6 flavors (served
alternately): cherry, vanilla, chocolate, strawberry, raspberry,
and butterscotch. The digestibility was about 3% lower with the
liquid diet than the fresh food. Nitrogen digestibility was
slightly improved in this study. The subjects were in negative
balance for calcium, potassium, and magnesium, but were otherwise
clinically normal. The subjects in this study disliked the diets
even more than in the previous series.
Dymsza et al. (1968) reviewed the development and
compositions of a number of different formulated diets, including
liquid, freeze-dehydrated, compressed tablets, bite-size pieces,
candy, and cookies. It was noted that solid, more normal forms
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of CDD's would be more acceptable. There has been little
interest in the use of CDD's for space travel in recent years.
Other Studies
Some of the medically oriented evaluations of CDD's will be
summarized in the remainder of this section. Eighteen medical
students (15 males, 3 females) were randomly assigned to consume
a monomeric diet (Mead Johnson 3200-AS), containing hydrolyzed
casein and medium chain triglycerides, or a polymeric diet (Mead
Johnson 3200-AU) which contained intact casein and no medium
chain triglycerides, for 12 days. The osmolarity of the
monomeric diet was about 700 mOsm per liter. The vitamin and
mineral contents were similar. The subjects disliked the
consistency and taste of both the monomeric and the polymeric
diet, and all subjects lost 2 to 3 pounds. Decreased serum
cholesterol was found in both groups after the diet study. Most
other blood test values were normal. Fourteen of the subjects
were given duodenal perfusions in order to study the effects on
bile salts and pancreatic enzymes (pancreatic trypsin, lipase,
and amylase). No pancreatic damage could be found with respect
to pancreatic enzyme secretions. Reduced bile salt secretion
(with pancreozymin stimulation) was found in the subjects on the
monomeric diet; however, the reduction was not statistically
significant. The 15 males swallowed radio-opaque markers of
vinyl tubing on day 7 of the diet. Delayed transit times (due to
the liquid aspects) were found in subjects ingesting both diets,
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when compared with data on normal diets from other studies. The
authors stated that the results indicate that the monomeric diet
is safe (Perrault et al., 1973).
McCamman et al. (1977) compared 3 CDD's in i0 volunteers (i
male and 9 females). The CDD's tested were Standard Vivonex
(monomeric), Flexical (monomeric), and Precision LR (low residue,
polymeric, Sandoz Nutrition). Each subject was given a
standardized control diet for 3 days, then one of the CDD's for
i0 days, then ate a normal diet for at least 5 days. Each
subject tested all 3 diets in randomized order using this
schedule. The subjects consumed calorie- and caffein-free
beverages and water as needed during the study. Stool weight on
Vivonex was significantly reduced compared with Precision LR.
Flexical produced stool weights between those of the other 2
diets. Differences in the frequency of bowel movements were not
significant. Both stool weight and frequency were lower than
data from subjects on normal diets. In general, the longer a
person is on a CDD, the more stool weight and frequency is I
reduced. The reduction in stool weight indicates greater
nutrient utilization on CDD's. No significant differences in the
fecal fat, ash, or moisture were detected on the 3 diets,
indicating normal absorption. Subjects excreted more nitrogen
than they took in (negative nitrogen balance) on all 3 diets and
experienced weight losses of an average of 1.92 to 2.59 pounds.
Weight losses of a couple of pounds are typical on beginning
intake of CDD's, possibly due to lowered weight of intestinal
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contents. The investigators reported that there was a
miscalculation of the amounts of each CDD required for the
subjects in this study. Due to the low protein to calorie ratios
of the 3 diets, at least 2000 kcal of each CDD should have been
given to the females. However, they received only 1500 to 1800
kcal.
The subjects ranked the CDD's according to taste, side
effects, and degree of difficulty in mixing the diets. Vivonex
was ranked as the best, and Precision LR was the second best.
Flexical was preferred by only 2 subjects. The subjects mixed
their CDD's with various beverages, which no doubt improved the
taste of these diets. It took all subjects a few days to get
used to the taste of the CDD's, especially Flexical. Side
effects included headache, sweating, weakness, constipation, and
diarrhea. The subjects experienced sensations of being too full,
when they returned to solid food after being on the liquid CDD's
during the study (McCamman et al., 1977).
The effects of 2 polymeric CDD's on fecal weight, fat
absorption, nitrogen excretion, and other factors were assessed
in i0 healthy college students (6 males, 4 females) by Kien et
al. (1981). The subjects ate normal diets for the first 12 days
of the study, after which they were randomly assigned to either
Isocal or Sustacal (Mead Johnson Company) for 12 days. They
could also drink unlimited water and carbonated beverages. The
subjects were given fecal markers to swallow on the ist, llth,
16th, and 26th days. The subjects maintained adequate body
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weights on both CDD's; no GI upsets were reported. The fecal
weights were slightly lower on Isocal than on the normal diet,
but the differences were not statistically significant. There
was significantly less fat in the stools of subjects on the CDD's
than the normal diets, indicating greater absorption. Nitrogen
absorption was 95% for Isocal and 98% for Sustacal.
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Table 24
Health Effects of CDD's in Humans
(Probable Causes Included Where Relevant)
Mechanical Problems Psychological Problems
tube/catheter contamination depression
leading to infection, GI psychoses
upsets negative body image
aspiration pneumonia with psychosomatic ailments
nasogastric tube feeding noncompliance with TPN
(due to regurgitation) routine
esophageal erosion/irritation unpleasant taste/odor
(nasogastric tube) of CDD's (especially
technical errors in administration of CDD's those with crystal-
tube/catheter clogging (ingredient interac- line amino acids)
tions, contaminated CDD's, incorrect CDD's)
GI Effects (contaminated CDD's,
high osmolality, rapid infusion rate) Chemical Reactions
nausea unstable nutrient
vomiting solutions
bloating drug/ingredient
cramping interactions
diarrhea
halitosis (crystalline amino acids
especially)
slower emptying of stomach
unpleasant taste and odor
reduced fecal bulk
fewer bowel movements
reduced microbial populations in
intestine
alterations in GI tract
hormones and enzymes
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Table 24 (continued)
Physiological Changes
enzyme activity
hormone secretions
nutrient excesses/deficiencies
fluid/electrolyte imbalances
serum cholesterol reduction with glucose as sole carbohydrate source;
serum cholesterol increase with sucrose as carbohydrate source (oralCDD's)
blood pressure reduction (oral CDD's)
lower fasting blood sugar (oral CDD's)
References (partial list of reports on health effects of CDD's):
i. Cataldi-Betcher et al., 1983
2. Greenberg et al., 1981
3. Heymsfield et al., 1979
4. Jeejeebhoy et al., 1976
5. Koretz and Meyer, 1980
6. Malcolm et al., 1980
7. Randall, 1984
8. Shenkin and Wretlind, 1979
9. Smith and Heymsfield, 1983
i0. Winitz et al., 1970a
ii. Winitz et al., 1970b
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Laboratory Animals
Studies to Develop CDD's
Representative studies of CDD's in various animal species are
presented below. The classical work in TPN was the demonstration
that nutrition could be successfully maintained by the parenteral
route in beagle puppies by Dudrick et al. (1968). At 8 weeks of
age each of 6 test puppies was compared to a litter mate control
puppy of similar size. Both test and control animals were given
standard oral diets until 12 weeks of age. At this time, the 6
test puppies were started on TPN, which had an equivalent number
of kilocalories to the standard diet. The TPN solutions included
fibrin hydrolysate, glucose, vitamins, minerals, and a fat
emulsion, and the nutrients were given over 21 to 23 hours per
day. The duration of TPN was from 72 to 256 days. The puppies
on TPN had greater weight gain and similar skeletal growth
compared to the controls.
The team of Winitz, Greenstein, Birnbaum, and others at the
National Institutes of Health developed oral CDD's in the 1950's
using rats for the most part. The CDD consisted of glucose,
vitamins, amino acids, minerals, and corn oil. The diet was
basically 80% glucose and 20% amino acids by weight. Several
variations of the CDD were tested in at least 5 to 6 weanling,
Sprague-Dawley rats of each sex. The animals were allowed to
feed ad libitum from 2 bottles containing tap water and the CDD
in each cage. The feeding studies were continued through the
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second generation for some of the CDD's. The original weanling
rats were mated at 120 or 186 days of age; offspring from these
rats were mated at 120 days of age in the first series of studies
(Greenstein et al., 1957).
Both fecal weight and frequency were reduced on the CDD's.
No evidence of degeneration of the teeth, gums, pancreatic
secretions, or other GI secretions was found in rats fed on CDD's
for over a year. These rats were then returned to normal rat
chow with no ill effects or adjustment problems. Growth of
weanling rats was best with a CDD containing more of the
nonessential amino acids (No. 26), in a ratio similar to those of
casein. Reproduction and lactation were also improved on this
diet.
Although the CDD's were readily accepted by the rats, during
the reproduction study an unexpected problem occurred. The rats
had never had solid food and had been raised in metabolic cages
with metal floors. After being mated, the females were given
nesting materials of wood shavings. The rats ate such large
quantities of the shavings that a number died before having their
litters. The problem was avoided by using foam rubber as a
nesting material; however, this certainly suggests that rats have
a preference for solid food.
Birnbaum, Greenstein, and Winitz (1957) performed metabolic
studies in male rats, using various CDD's. They found that
nitrogen retention (for protein synthesis) can only be increased
to a certain point, beyond which greater dietary intake results
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in less nitrogen retention. Birnbaum, Winitz, and Greenstein
(1957) then investigated the essential and nonessential amino
acid requirements in weanling male rats using CDD's to allow for
quantitative dietary manipulation. They concluded that
nonessential amino acids are actually needed in certain
proportions for optimum health.
The investigators also studied the effect of varying the
carbohydrate source in CDD's on growth in weanling, male,
Sprague-Dawley rats. The sugars tested included D-glucose,
D-sucrose, D-fructose, and D-glucosamine (tested for 3 weeks with
the first 3 and 6 weeks for the last one). Weight gains were
highest in the CDD containing sucrose, mainly because the rats
ate much more of this diet. The amount of D-glucosamine in the
diet was varied from 2.5 to 16%, with the remainder of the
carbohydrate source being glucose. Increased D-glucosamine was
correlated with decreased growth rates, due to decreased
ingestion of the diet (winitz, Birnbaum, and Greenstein, 1957).
Similar studies were conducted over 3 weeks to test the effect of
various forms of arginine on growth in weanling male rats. The
best growth response was produced by L-arginine, although
D-arginine also promoted growth compared to CDD's without
arginine. The addition of L-arginine to a diet deficient in
nonessential amino acids greatly improved growth and tended to
mask nutrient deficiencies (Winitz, Greenstein, and Birnbaum,
1957).
Some growth studies were also done on weanling white mice
104
(N.I.H. strain) of both sexes. The mice were given one of 2
CDD's (No. 3 or No. 26) ad libitum for 3 weeks. Control mice
were given Purina laboratory chow. The mice readily consumed the
CDD's. Growth rates were much better with CDD No. 26 than with
No. 3. The growth of mice fed No. 26 was similar to control
animals. The weanling mice did poorer on No. 3 than weanling
rats (Birnbaum et al., 1958).
The final report in the above series of studies (Greenstein
et al., 1960) summarizes the final CDD's that were developed and
results of various growth studies. The major difficulty in
designing the CDD was the ability to incorporate the fat and
fat-soluble vitamins successfully in a stable, water-soluble
form. Earlier CDD's had employed separate fat supplements of
corn oil. The problem was overcome by adding a Polysorbate 80
(an emulsifier) and ethyl linoleate mixture to an alcohol
solution of fat-soluble vitamins. This formed an oil and water
emulsion, which could be mixed with the other components in
aqueous solution. Various forms of the fat component were added
to CDD No. 26 and compared with No. 26 plus separate corn oil
supplements in weanling rats for 82 days. Too much Polysorbate
80 (12 grams per 2 liters CDD) produced diarrhea in the rats.
The diet was reformulated to contain 6 grams Polysorbate 80 and 4
grams ethyl linoleate per 2 liters diet. This CDD was designed
for eventual application to parenteral CDD's in humans.
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Studies to Evaluate the Effects of CDD's
The effects of enteral CDD's on the GI tract of rats were
studied by Young et al. (1980). Control rats were fed Lab Blox
Chow at the same caloric level. Male, Sprague-Dawley rats were
fed the CDD through a surgically implanted intragastric tube for
2 weeks. Control animals were given distilled water through the
intragastric tubes. The CDD's tested included Vivonex, Vivonex
HN, Flexical, and Ensure. Rats in the control group gained more
weight than rats fed any of the CDD's. The lower weight gains
were statistically significant in rats fed Flexical or Vivonex.
The percentage of fat in the livers of animals fed Vivonex or
Flexical was significantly higher than in the controls. The
weight of the pancreas was significantly lower in Vivonex and
Flexical animals than in the controls, and the activity of
certain pancreatic enzymes was significantly lower in these
groups and the Ensure group as well. Maltase activity of
proximal small intestinal sections was significantly greater in
the vivonex, Vivonex HN, and Ensure rats than in the controls.
Mucosal weights in intestines of all CDD groups were
significantly lower than controls on regular chow. The lack of
fiber in the CDD's may have contributed to the reduced mucosal
weight. Total protein and DNA levels in the intestinal muscosa
were also lower in CDD groups. The authors stated that the fatty
liver development (due to Vivonex and Flexical) may have been
because of an inadequate nitrogen to calorie ratio, preventing
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the production of phospholipids that carry fats out of the liver.
Either the use of the intragastric route for administering CDD's
or the compositions may account for some of the other intestinal
changes (pancreatic enzyme activity reduction, decreased weight
of small intestinal mucosa, and increased intestinal maltase
activity). Stimulation from normal, oral food intake may also
affect the release of various secretions in the GI tract.
In order to test the effects of oral versus intragastric
administration of CDD's on the GI tract, Young et al. (1982) fed
equivalent caloric levels of Vital, Vivonex, Vivonex HN, and
Flexical to rats by these routes. Controls were given a liquid
casein diet (II6EC from Grand Island Biochemical Company) by both
routes. Oral intake was achieved via measured animal drinking
tubes; all animals in these groups were also implanted with
intragastric tubes. The duration of the feeding study was 2
weeks. In general, the GI tract changes were greater due to CDD
composition than from route of administration, although effects
of the route were noted. The intragastric groups all had lower
body weight gains, especially in the Flexical, Vivonex, and
control liquid casein groups. Fat content of livers was higher
in rats given Vivonex and Vivonex HN, as opposed to Vital,
Flexical, or the control liquid; effects of route were not
significant. Pancreatic amylase activity was significantly
affected by both diet composition and route. Enzyme activity was
significantly higher in intragastric route rats given Vital,
Flexical, and Vivonex HN. Proximal intestinal mucosa sections
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had significantly lower weights, lower protein, and DNA in rats
fed all CDD's compared with control liquid, regardless of route.
The authors indicated that a complete understanding of the
complex interactions of nutrient influences on the GI system
await further research.
The effects of parenteral versus oral administration of CDD's
on the structure and enzymes of the intestinal mucosa were
investigated by Levine et al. (1974) in male, Sprague Dawley
rats. Equivalent CDD's were given to 2 groups of rats for 7
days. One group was allowed to feed orally, ad libitum; the
other received the diet by TPN. Intestinal hypoplasia and
atrophy (statistically significant) due to the intravenous CDD
route were found. Effects due to TPN included a reduction in the
total amount of the small intestine, decreases in proximal
mucosal weight, total mucosal protein, mucosal DNA, mucosal
height, reduced amounts and specific activities of maltase and
sucrase, and a reduced amount of lactase. The results indicate
that oral intake of food is important in at least certain aspects
of normal intestinal structure and function.
The effects of CDD osmolality on nutrient absorption, GI side
effects, and other factors were investigated in pigs by Case et
al. (1981a; 1981b). Pigs have GI systems similar to those of
humans. In the first study, 20 Yucatan miniature pigs were given
oral CDD's of 5 different osmolalities from 250 to 700 mOsm per
kg. A commercial polymeric CDD, Ensure (Ross Laboratories), was
adjusted to the different osmolalities by changing the sucrose to
108
corn syrup solids ratio. The CDD's were ingested (usually in one
minute) by the pigs 3 times per day for 3 days. On the fourth
day, part of the first meal contained water and sucrose labelled
with radioactive tracers. Samples of plasma were taken from the
pigs at various intervals from I0 minutes to 4 hours after the
meal. Carbohydrate absorption rates and amounts absorbed
increased as the osmolalities increased, particularly during the
first hour. Plasma glucose levels increased quickly in the first
20 minutes and were significantly less in pigs who ate the 250
mOsm per kg diet. Water absorption rate and amount were
significantly greater at the 700 mOsm per kg level in the first
30 minutes. Water absorption rates and amounts were not
significantly different at the other osmolalities. Rapid
detection of labelled water, sucrose, and glucose in the plasma
at all osmolalities was noted and suggests increased rate of
gastric emptying due to the CDD's.
A second, similar study by Case et al. (1981b) was performed
in 48 Yucatan miniature pigs. CDD's having osmolalities from 340
to 700 mOsm per kg were fed to the pigs for 3 days as in the
first study. On the fourth day labelled doses of water, sodium
chloride, sucrose, and chromium were included in the first meal.
Plasma samples were collected during the following hour, after
which the carbohydrate levels and osmolalities of the stomach and
small intestine contents were determined. Average osmolalities
of the contents of various segments of the intestine were
significantly reduced at 60 minutes compared with 30 minutes
109
after the meal in all CDD's. Stomach emptying and dilution of
contents were determined by comparing nonabsorbable chromium
marker recovery rates with those of the absorbable markers
(sodium chloride, water, and sucrose). CDD osmolality had no
significant effects on stomach emptying (unlike the first study)
or dilution. Carbohydrate, sodium, potassium, and water
absorption increased as CDD osmolality increased. The
osmolalities of the intestinal contents and stomach of pigs
ingesting the different CDD osmolalities reached similar levels
(453 mOsm per kg in the duodenum) within an hour after the meal.
The authors concluded that a moderate osmolality of 700 mOsm per
kg may be clinically advantageous, because nutrient absorption is
enhanced, and nutrients can be given in smaller fluid levels.
The 700 mOsm per kg level was not considered responsible for many
reported GI upsets in other studies. The results of studies in
healthy animals may differ from results in those with GI system
diseases.
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Summary
The reasons for using some type of CDD include
gastrointestinal problems, traumatic injuries, severe burns,
major surgery, coma, persistent vomiting, anorexia, preparation
for GI tract diagnostic procedures, food allergies, mental
retardation, and cancer. The most common medical reasons for
using parenteral CDD's include inflammatory bowel diseases,
fistulas of the GI tract, and abdominal surgery. The necessity
of using CDD's for some of these reasons is controversial, as
well as the type of CDD and route of administration. The major
categories of CDD complications involve mechanical problems with
administering the diets (such as contamination or blockage of
catheters or nutrient solutions, aspiration of stomach contents,
etc.), physiological changes (nutrient deficiencies or excesses,
fluid shifts, alterations in hormone or enzyme levels, etc.),
gastrointestinal side effects (diarrhea, nausea, vomiting,
cramping, constipation, etc.), interactions with ingredients or
drugs, and psychological problems associated with the
unnaturalness and inconvenience of the CDD's.
An area of disagreement regarding the effects of CDD's in
humans involves changes in the GI tract. For example, CDD's have
been found to reduce intestinal microbial populations,
particularly with glucose as the carbohdydrate source (Winitz et
al., 1970b). Other studies have contradicted this finding
(Koretz and Meyer, 1980); however, variations in diet composition
may account for the opposite results. Similarly, opposing data
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are available on the CDD-induced changes in enzyme and hormone
secretions of the pancreas, stomach, and other organs in the GI
system. Since there are few well-controlled studies on many of
these effects, this controversy cannot be resolved at this time.
Total parenteral nutrition (TPN) has been used clinically
since the late 1960's. This extreme form of CDD is to be
utilized when enteral administration is impossible for some
reason. Documentation of patients on home TPN for long periods
has helped improve the design of nutrient solutions and has
increased general knowledge of human nutrient requirements.
Despite increased knowledge, nutritional needs can vary
considerably among both healthy and diseased individuals.
A review of CDD studies in healthy humans shows that a major
disadvantage of liquid diets involves aesthetic aspects, such as
bad taste and odor, monotony, and consistency. The reduction in
frequency and amount of fecal elimination has been bothersome to
some subjects, and others have had some GI upsets. Weight losses
have also been reported due to inadequate dietary intake and to
the lack of bulk from solid food on the intestine.
Only a few of the available feeding studies in laboratory
animals have been summarized in this report. Early work with
puppies (TPN) and weanling rats (oral CDD's) proved that CDD's of
the correct composition could substitute completely for normal
diets in these species. Atrophy of the GI system due to
inactivity during TPN or lack of solid foods with enteral CDD's,
has been of concern to many researchers. Some changes, such as a
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reduction in the weight of the intestinal mucosa and decreased
gut hormone secretions, have been reported in rats and other
species on TPN. Oral CDD's have been reported to increase GI
hormone and enzyme secretions or mucosal weights in some studies
and to decrease these parameters or exert no effects in others.
Composition and also route of administration have been found to
influence many of the effects of CDD's.
113

CHAPTER IV
NUTRIENT TOXICITY AND INTERACTIONS
The selection of foods to be used during space missions will
be constrained by safety considerations arising both from
potential hazards of the various nutrients and from their
interactions with other nutrients or other substances.
Nutrient Toxicity
Much of the attention in nutrition is to nutrient
deficiencies, particularly of vitamins and trace elements. Also
there has been much public concern over unhealthy dietary levels
of various fats, sugar (sucrose), and sodium. It should be noted
that almost any substance can be harmful at high enough levels in
the diet. The idea that if a certain amount is good, twice that
amount is twice as beneficial, has been common regarding both
vitamins and trace elements.
In order to clarify this issue, the effects of high doses of
various nutrients and toxic levels and/or maximum recommended
dietary levels of these nutrients are summarized in Table 25.
The emphasis is not on acute doses of nutrients, in which one
very large dose produces adverse symptoms, but on chronic intake
of excess levels. In most cases, the exact maximum safe intake
for periods of months or years has not been determined. It may
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take a very long time for symptoms to develop when the safe
intake level of a nutrient is exceeded on a daily basis. A
useful indication of a safe nutrient intake level is the
estimated amount in a typical diet. This level has been included
in Table 25, if available.
The fat-soluble vitamins are potentially toxic if
overingested, because these vitamins tend to be stored in the
liver or in fat deposits. Vitamins A and D have been most
commonly associated with toxic effects.
The water-soluble vitamins are generally less toxic, because
of their rapid excretion, although toxic effects of megadoses
(g per day) of nicotinic acid, vitamin C, and pantothenic acid
have been reported. Adverse neurological effects of excess
vitamin B6 were also reported recently by Schaumburg et al.
(1983). Daily ingestion of 2 to 6 g over periods of 2 to 40
months gradually produced extreme loss of coordination and
feeling in 7 adults. These individuals had trouble walking and
manipulating objects with their hands. The severity of the
symptoms improved slowly 2 months after the vitamin B 6
supplements were discontinued. This was one of the first reports
of vitamin B 6 toxicity, although chronic large doses (200 mg per
day) of vitamin B 6 have been found to induce dependency in
healthy humans (National Research Council, 1980).
The toxicity of some water soluble vitamins could be due to
the presence of a small impurity, the effect of which is
magnified at very high doses (Rudman and Williams, 1983). In the
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vitamin B 6 case study above, the affected individuals took
supplements ranging from i000 to about 3000 times the recommended
daily allowance of 2.0 to 2.2 mg vitamin B 6. A recent
biochemistry book states that "There is no known toxicity of
vitamin B6" (Martin et al., 1983, page 105). Before
self-prescribed megavitamin usage became common after 1970, few
people would have encountered such excess amounts of a single
vitamin. Vitamin B 6 has been reported to be helpful in treating
premenstrual fluid retention, certain behavioral problems, and
for increasing muscle development in weight-lifters (Rudman and
Williams, 1983). These beneficial effects have not been
adequately researched at this time.
Except for the controversial role of sodium in hypertension
(discussed in Chapter II), the minerals and electrolytes
(calcium, chlorine, magnesium, and potassium) are not toxic in
normal humans, due to rapid excretion. Most of the trace
elements can have toxic effects when large doses are taken
(Martin et al., 1983). Some of the heavy metals, such as
chromium and manganese, are more frequently associated with
occupational toxicity by inhalation (Hawley, 1971; National
Research Council, 1980).
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Table 25
Toxic Limits of Ingested Nutrients
Approximate
Maximum Safe
Chronic In-
take; Amount
in Typical Some Reported
Nutrient U.S. Diet Toxic Levels Adverse Effects
Vitamins
A maximum: >50,000 IU/day 3 headache, bone pain,
25,000 iO/day 3-, dizziness, skin 2
typical: not 3 peeling ;
specified excess carotenes:
yellow skin, no
other known effects 3
D maximum: i00,000 IO/day elevated serum cai-
200 IO/day3; for several I cium, nausea
typical: not_ months vomiting, kidney 1
specified 5 damage
E maximum: not_ 400-1000 IO 3 blurred vision, 2
specifiedS; headaches
typical: 3
10-20 IU/day
K oral therapeutic large doses of hemolytic anemia,
dose for vitamin varying amounts 1'2 liver damage
K deficiency: by synthetic
1.5-2 mg/day I, water-soluble
5-10 mg/day4; vitamin K1'2
typical: 300-500_
mcg/day 5
2
Thiamin maximum: not usually nontoxic --
specified3;
typical: not 3
specified
2
Riboflavin maximum: not 3 usually nontoxic no cases 3
specified ; reported
typical: not 3
specified
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Table 25 (continued)
Approximate
Maximum Safe
Chronic In-
take; Amount
in Typical Some Reported
Nutrient U.S. Diet Toxic Levels Adverse Effects
maximum: not^ 200 mg/day 3 induced dependency 3-B 6
specifiedS; for 1 mo. ; severe loss of '
typical: not 3 2-6 g/day for 6 feeling and
specified 2-40 mo. coordination 6
BI2 maximum: not 3 usually nontoxic 2 --
specified ;
typical: 5-153
mcg/day
Folacin maximum: at least usually nontoxic --
1-2 mg/day
acceptable 3
in diet ;
typical: .379- 3
1.097 mg/day
Niacin maximum: 34 mg/day 3 g/day nico- flushing of skin,
(including tryp- tinic acid 3 decrease in
serum 3
tophan, 60 mg lipids, GI upsets
= 1 mg niacin);
typical: 8-17 mg
niacin/day (plus
500-1000 mg 3
tryptophan)
Pantothenic maximum: intakes 10-20 g/day 3 diarrhea, fluid 3
acid to 20 mg/day retention
reported with
no toxicity3;
typical: 5-203
mg/day
Biotin maximum: not usually nontoxic 2 --
specified; typi-
cal: 100-3003
mcg/day
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Table 25 (continued)
Approximate
Maximum Safe
Chronic In-
take; Amount
in Typical Some Reported
Nutrient U.S. Diet Toxic Levels Adverse Effects
C maximum: not3 megadoses in2 kidney stones,
specified ; grams/day diarrhea, impaired
typical: not_ vitamin BI2
specified5
absorption2;
absorption of
unsafe amounts3
of iron
Minerals
Calcium maximum: up to excess usually --
1500 mg/day with excreted in 2,3
no reported healthy persons
problems3;
typical: not^
specifiedj
Chlorine maximum: 5.1 g/day3 none specified
typical: 1.95-_ (2 3)
5.9 g/dayj
Magnesium maximum: not3 relatively non- breathing problems,_
specified ; toxic orally if impaired reflexesZ;
typical: 24013 kidneys are diarrhea from very 3mg/2000 kca operating ade- la ge doses
quately2;3
3-5 g at once
Phosphorus maximum: not_ relatively non- low ratio of cal-
specifiedJ; toxic with normal cium:phosphorus--
typical: 1.5-3 kidney function; bone loss, cai-
1.6 g/day low calcium: cium loss2'3
phosphorus ratio
(should be I:i) 2
may be hazardous ,3
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Table 25 (continued)
Approximate
Maximum Safe
Chronic In-
take; Amount
in Typical Some Reported
Nutrient U.S. Diet Toxic Levels Adverse Effects
Potassium maximum: 5.6 >18 g/day (sudden high doses can be
g/day 3 ; increased in- fatal (cardiac
typical: 1.95- 3 take especially) 3 arrest); ulcers;
5.9 g/day altered sodium:
potassium ratio
be factor in 2
hypertension [3
Sodium maximum: 3.3- 3 chronic high hypertension in
6 g/day ; intake (exact susceptible 3
typical: 2.3- levels unknown) persons
6.9 g/day 3
Trace
elements
Chromium maximum: 200 most toxic chromium poisoning 1
mcg/day3; when inhaled 5
typical:
60 mcg/day 3
Copper maximum: 3 mg/day3; low dietary copper poisoning:
typical: toxicity in polyneuritis 1
<1-5 mg/day 3 healthy persons 3
Fluorine maximum: 4 mg/day3; • >20 mg/day for 3 fluoride toxicity 3-
typical: long periods weakness, nausea,
1-4 mg/day 3 vomiting, tremors,
hypotension, coma,l
breathing problems
Iodine maximum: 3003 >300 mcg/day, goiter 2'3" iodinef
mcg/day ; exact level poisoning: vomiting,
typical: 64- 3 not specified 3 metallic taste in
677 mcg/day mouth, thirst,
clammy skin,
breathing problems,l
convulsions
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Table 25 (continued)
Approximate
Maximum Safe
Chronic In-
take; Amount
in Typical Some Reported
Nutrient U.S. Diet Toxic Levels Adverse Effects
Iron maximum: 753 lethal dose (as iron poisoning:
mg/day ; ferrous sulfate) vomiting, diarrhea,
typical: not 3 about 200-250 mg/ hypotension, rapid 1
glven kg or about 14- heart rate, shock
17.5 g iron in ^
a 70 kg adult j
Manganese maximum: 5 mg/day3; more toxic when manganese poison-.
typical: 2- inhaled or^ ing: polyneurltls ;2
9 mg/day 3 injected j psychosis
Molybdenum maximum: 500. 10-15 mg/daY;3 gout symptoms--
mcg/dayJ; 540 mcg/aay higher intake;
typical: i00-_ copper losses-- 3
460 mcg/day _ lower intake
1
Selenium maximum: mainly reported selenium poisoning
200 mcg/day3; in laboratory 3
typical: 50- animals
200 mcg/day 3
Zinc maximum: 15 mg/ 2 g or more (as vomiting, otherq
day plus diet- zinc sulfate) 3 GI upsets-; 1
ary intake = in one dose polyneuritis
30 mg/day3 ;
typical: 6-
15 mg/day _
References:
I. Holvey, 1972
2. Martin et al., 1983
3. National Research Council, 1980
4. Physician's Desk Reference, 1984
5. Hawley, 1971
6. Schaumburg et al., 1983
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Dietary Interactions
Some examples of the known interactions in the diet are given
in Table 26. Nutrient requirements may be altered because of
environmental stress (such as extremes of temperature), injury,
disease, or major surgery. In addition, the high intake of
nutrient A may cause increased excretion or utilization of
nutrient B, which would raise the requirements for B. As an
example, higher protein levels from purified protein sources can
increase calcium excretion (National Research Council, 1980).
High protein intake also can increase the need for zinc and
vitamin B 6. A higher intake of kilocalories (energy) increases
the need for thiamin, because thiamin is necessary for a number
of metabolic functions. The requirement for vitamin E varies
with the amount of polyunsaturated fatty acids in the diet. A
higher requirement exists when intake is high and vice versa.
Sodium loss in sweat during work at extremely high temperatures
may raise the sodium requirement. High zinc intake may increase
an existing copper deficiency (National Research Council, 1980),
and high phosphate and calcium levels can make a zinc deficiency
worse (Martin et al., 1983).
Another type of interaction is alteration in nutrient
absorption or bioavailability. The presence of at least 30 to 90
g of meat, fish, or poultry or at least 25 to 75 mg vitamin C in
a meal increases iron absorption. A meal with the highest iron
availability is attained when greater than 90 g of meat, fish, or
poultry are present, when greater than 75 mg vitamin C are
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present, or when both 30 to 90 g meat, fish, or poultry and 25 to
75 mg vitamin C are present (Monsen et al., 1978). Excess zinc,
copper, manganese, calcium or phosphate salts, and tannic acid
(in tea) can decrease iron absorption. The fiber and phytate in
plants (especially whole grain cereals and legumes) decrease the
absorption of trace elements (zinc, iron, copper, manganese, and
chromium), magnesium, and calcium. Soy protein also inhibits the
utilization of minerals (Howe and Hoff, 1982). Mineral
absorption can also be inhibited by high protein, fat, or oxalate
levels. A high copper level may block zinc absorption whereas a
high molybdenum intake may disrupt copper metabolism (Martin et
al., 1983).
Suppression or inactivation of one nutrient by ingestion of
another substance is a third type of interaction. This may
involve a direct chemical inactivation, such as thiaminase in raw
fish inactivating thiamin, avidin in raw egg white inactivating
biotin, or vitamin C inactivation by heat or oxidation. This
type of interaction can also be the indirect result of a
substance on the production or utilization of a nutrient. A
typical example of this is the reduction in the number of
intestinal bacteria that occurs during antibiotic therapy, which
may lead to deficiencies of biotin or vitamin K (Martin et al.,
1983; National Research Council, 1980). Many other therapeutic
drugs can alter the nutrient balance of the body.
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Table 26
Some Interactions in the Human Diet
A. Alterations in Nutrient Requirements
i. High protein intake increases requirements for zinc
(Martin et al., 1983), calcium, and vitamin B 6 (National
Research Council, 1980)
2. Increase in total energy (kcal) intake (especially
carbohydrate) increases the need for thiamin, because this
vitamin is needed for many metabolic reactions, especially
those involving carbohydrates (National Research Council,
1980)
3. Lower intake of polyunsaturated fatty acids lowers both
intake of and requirement for vitamin E (National Research
Council, 1980)
4. Severe environmental or other stress, such as severe injury
or illness, (note that abnormal eating habits may be
associated with stress) increases the vitamin C requirement
(Howe and Hoff, 1982; National Research Council, 1980)
5. Some B vitamin requirements may also be increased by
stressors, such as severe illness or trauma (Shenkin and
Wretlind, 1979)
6. Large amounts of zinc may make a copper deficiency worse
(National Research Council, 1980)
7. High phosphate and calcium levels in the diet could make a
zinc deficiency worse (Martin et al., 1983)
8. Extremely vigorous work in high temperatures may lead to
increased sodium losses in sweat, which would raise the
sodium requirement (National Research Council, 1980)
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Table 26 (continued)
B. Effects on Nutrient Absorption/Bioavailability
i. Vitamin C increases iron absorption (Howe and Hoff, 1982) in
a meal containing at least 25-75 mg vitamin C (Monsen et al.,
1978); vitamin C decreases copper absorption (Martin et al.,
1983)
2. Meat, fish, or poultry (at least 30 to 90 g) in a meal
increases iron absorption (Monsen et al., 1978)
3. Excess zinc, copper, manganese, salts of calcium and
phosphate, and tannic acid in tea decrease iron absorption
(Howe and Hoff, 1982; National Research Council, 1980)
4. Zinc, iron, copper, manganese, chromium, magnesium, calcium--
absorption of these elements decreased by fiber and phytate
in plants, particularly whole grain cereals and legumes (Howe
and Hoff, 1982)
5. Mineral absorption adversely affected by excess protein,
fat, and oxalates (Martin et al°, 1983)
6. Dietary soy protein--decreased utilization of minerals
(calcium, magnesium, phosphorus, copper, and manganese) (Howe
and Hoff, 1982)
7. Excess molybdenum may disrupt copper metabolism (Martin et
al., 1983)
8. High copper level in diet may block zinc absorption (Martin
et al., 1983)
C. Suppression/Inactivation of Nutrients
i. Large intake of raw egg white, prevents biotin from being
utilized due to the protein, avidin (National Research
Council, 1980)
2. Antibiotic therapy reduces intestinal microorganisms and
consequently biotin and vitamin K synthesis (Martin et al.,
1983)
3. Thiamin--destroyed by thiaminase in raw fish (Martin et al.,
1983)
4. Vitamin C becomes nonfunctional due to heat and oxidation
(National Research Council, 1980)
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CHAPTER V
CONCLUSIONS
There are approximately 40 nutrients known to be required in
the daily diet. Additional essential substances may be
identified in the future. Liquid alternatives to a normal, solid
diet have been used most frequently for medical reasons, and the
scientifically formulated, chemically defined diets (CDD's) have
been in use for about 20 years. The administration of CDD's to
humans has saved lives and has also increased our knowledge of
human nutrition. The health of people fed by CDD's for long
periods (months to years) will continue to be a source of
information on requirements for nutrients needed in very small
amounts. In the past decade, requirements for selenium,
molybdenum, chromium, and biotin have been refined from
experience with long-term intravenous CDD's (TPN, or Total
Parenteral Nutrition).
There is a vast amount of literature on both CDD's and
nutrition in general, and only a portion of the available sources
has been reviewed in this report. For more details on the
various aspects of CDD's, the original references cited should be
consulted. The reviews on TPN include Phillips and Odgers
(1982), Shenkin and Wretlind (1979), and Shils (1980). Enteral
CDD's are covered by Cataldi-Betcher et al. (1983), Heymsfield et
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al. (1979), Koretz and Meyer (1980), Randall (1984), and Smith
and Heymsfield (1983). The definitive source for nutrient
requirements in the United States is the National Research
Council (1980). Detailed biochemical information on the
nutrients is available in the text by Martin et al. (1983) and in
many other sources.
The effects of various types of CDD's in humans demonstrate
an important consideration in designing diets for long-term space
missions. This is that adverse reactions can occur with any
alteration in the normal eating pattern, even if the new diet is
nutritionally complete. Adverse effects can either be
psychological or physiological, and gastrointestinal symptoms
would probably be the most likely physiological ones encountered
in space travel. The psychological effects might include extreme
dislike of the taste and reduced variety of a space diet,
depression, hostility, loss of appetite, and psychosomatic
complaints. Another nutritional consideration is the effect of
possible decreases in the number of intestinal bacteria, which
could lead to deficiencies of biotin or vitamin K; nutrient
toxicities; and adverse nutrient interactions.
A final note is that many of the adverse effects of CDD's are
related either to the liquid form or to the method of
administration (nasogastric tubes, IV, etc.). Fewer problems
might be encountered with a special diet that is as nutritionally
complete as the currently available CDD's, but with more
interesting texture and improved taste, so that the diet would be
128
more readily accepted. Now that many of the technical problems
in providing all of the essential nutrients have been solved,
more attention can be focused on making the diets more pleasant
to consume.
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